Alogliptin vs Saxagliptin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline

Alogliptin · Nesina

Marketed by Takeda Pharmaceutical Company and partners

Approved in Type 2 Diabetessmall molecule
Partial signal

NCT00286429 · Phase 3 · completed

The 390-participant trial was randomized, quadruple-blind, and placebo-controlled, with 130, 131, and 129 participants assigned to placebo, alogliptin 12.5 mg, and alogliptin 25 mg, respectively. Both primary HbA1c comparisons were statistically significant in favor of alogliptin, but HbA1c is a surrogate measure, so the evidence does not establish a strong clinical-outcome grade.

Next expected readout: December 2026 · NCT07093476 (registry estimate)

Reported efficacy

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) (missed)

Result source: NCT02856113

Saxagliptin · Onglyza

Rights held by AstraZeneca and partners; US product discontinued

Approved in Type 2 Diabetessmall molecule
Reliable signal

NCT00121667 · Phase 3 · completed

Large randomized, double-blind, placebo-controlled phase 3 trial (743 treated participants across three saxagliptin doses and one placebo arm, all on background metformin). The primary endpoint was change from baseline in hemoglobin A1c at Week 24, an accepted hard glycemic measure for type 2 diabetes, and every saxagliptin dose showed a statistically significant improvement versus placebo (adjusted differences of -0.73, -0.83, and -0.72 percentage points, each p<0.0001). Because the trial was adequately powered, double-blind, and placebo-controlled, and the primary comparison was met, this is strong evidence for saxagliptin's efficacy.

Next expected readout: February 2027 · NCT02969798 (registry estimate)

Reported efficacy

Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07) (met)

Result source: NCT00121667

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlogliptinSaxagliptin
HbA1c, change-0.7% vs -0.1%−0.6 vs placebo25 mg QD · wk 26 · n 126NCT00286429
285 other results
  • -0.6% vs -0.0% 25 mg QD · wk 26 · n 128 · Phase 3 · primary NCT00286455
  • 0.1% vs -0.0% 25 mg · wk 26 · n 54 · Phase 3 · primary NCT02856113
  • -0.5% vs 0.1% 25 mg QD · wk 26 · n 104 · Phase 3 · primary NCT01023581
  • -0.9% vs -0.1% 25 mg · wk 26 · n 123 · Phase 3 · primary NCT00328627
  • -0.8% vs -0.2% 25 mg QD · wk 26 · n 195 · Phase 3 · primary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 26 · n 203 · Phase 3 · primary NCT00286442
  • -0.6% vs -0.1% 12.5 mg QD · wk 26 · n 130 · Phase 3 · primary NCT00286429
  • -0.6% vs -0.0% 12.5 mg QD · wk 26 · n 131 · Phase 3 · primary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 26 · n 104 · Phase 3 · primary NCT01023581
  • -0.6% vs -0.1% 12.5 mg · wk 26 · n 122 · Phase 3 · primary NCT00328627
  • -0.7% vs -0.2% 12.5 mg QD · wk 26 · n 196 · Phase 3 · primary NCT00286494
  • -0.6% vs -0.1% 12.5 mg QD · wk 26 · n 210 · Phase 3 · primary NCT00286442
  • -1.3% vs -0.1% 25 mg + 15 mg · wk 26 · n 127 · Phase 3 · primary NCT00328627
  • -1.4% vs -0.1% 25 mg + 30 mg · wk 26 · n 124 · Phase 3 · primary NCT00328627
  • -1.6% vs -0.1% 25 mg + 45 mg · wk 26 · n 126 · Phase 3 · primary NCT00328627
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 26 · n 102 · Phase 3 · primary NCT01023581
  • -1.6% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 26 · n 111 · Phase 3 · primary NCT01023581
  • -1.3% vs -0.1% 12.5 mg + 15 mg · wk 26 · n 130 · Phase 3 · primary NCT00328627
  • -1.4% vs -0.1% 12.5 mg + 30 mg · wk 26 · n 128 · Phase 3 · primary NCT00328627
  • -1.6% vs -0.1% 12.5 mg + 45 mg · wk 26 · n 127 · Phase 3 · primary NCT00328627
  • -1.0% vs -0.4% wk 16 · n 90 · Phase 3 · primary NCT01289119
  • -0.9% vs -0.4% wk 16 · n 98 · Phase 3 · primary NCT01289119
  • -0.8% vs -0.4% wk 16 · n 60 · Phase 3 · primary NCT01289119
  • -1.0% vs -1.1% 25 mg · wk 26 · n 160 · Phase 3 · primary NCT00395512
  • -0.8% vs -0.7% 25 mg · wk 52 · n 382 · Phase 3 · primary NCT00856284
  • -0.7% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 303 · Phase 3 · primary NCT00432276
  • -0.9% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 303 · Phase 3 · primary NCT00432276
  • -1.0% vs 0.0% 12.5 mg QD · wk 12 · n 76 · Phase 2/3 · primary NCT01263483
  • -1.7% vs -1.1% 25 mg + 30 mg · wk 26 · n 158 · Phase 3 · primary NCT00395512
  • -0.7% vs -0.6% 25 mg · wk 104 · n 382 · Phase 3 · primary NCT00856284
  • -0.8% vs -0.7% 12.5 mg · wk 52 · n 371 · Phase 3 · primary NCT00856284
  • -0.7% vs 0.3% 25 mg QD · wk 12 · n 104 · Phase 2/3 · primary NCT01318083
  • -1.0% vs -0.2% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 113 · Phase 2/3 · primary NCT01318070
  • -0.9% vs 0.0% 25 mg QD + 0.2 mg TID · wk 12 · n 79 · Phase 2/3 · primary NCT01263483
  • -1.6% vs -1.1% 12.5 mg + 30 mg · wk 26 · n 158 · Phase 3 · primary NCT00395512
  • -0.7% vs -0.6% 12.5 mg · wk 104 · n 371 · Phase 3 · primary NCT00856284
  • -0.6% vs 0.3% 12.5 mg QD · wk 12 · n 104 · Phase 2/3 · primary NCT01318083
  • -0.9% vs -0.2% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 111 · Phase 2/3 · primary NCT01318070
  • 0.3% vs 0.8% 25 mg · wk 52 · n 62 · Phase 3 · secondary NCT02856113
  • 0.1% vs 0.5% 25 mg · wk 39 · n 62 · Phase 3 · secondary NCT02856113
  • -0.7% vs -0.2% 25 mg QD · wk 20 · n 126 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 25 mg QD · wk 20 · n 128 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 25 mg QD · wk 20 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.2% 25 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.3% 25 mg QD · wk 20 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 20 · n 203 · Phase 3 · secondary NCT00286442
  • -0.2% vs -0.2% 25 mg · wk 18 · n 62 · Phase 3 · secondary NCT02856113
  • -0.8% vs -0.2% 25 mg QD · wk 16 · n 126 · Phase 3 · secondary NCT00286429
  • -0.7% vs -0.1% 25 mg QD · wk 16 · n 128 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 25 mg QD · wk 16 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.3% 25 mg · wk 16 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.3% 25 mg QD · wk 16 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 16 · n 203 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 25 mg QD · wk 12 · n 126 · Phase 3 · secondary NCT00286429
  • -0.7% vs -0.1% 25 mg QD · wk 12 · n 128 · Phase 3 · secondary NCT00286455
  • -0.4% vs -0.3% 25 mg · wk 12 · n 62 · Phase 3 · secondary NCT02856113
  • -0.5% vs 0.1% 25 mg QD · wk 12 · n 112 · Phase 3 · secondary NCT01023581
  • -0.9% vs -0.3% 25 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.2% 25 mg QD · wk 12 · n 195 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.2% 25 mg QD · wk 12 · n 203 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 25 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 25 mg QD · wk 8 · n 128 · Phase 3 · secondary NCT00286455
  • -0.5% vs 0.1% 25 mg QD · wk 8 · n 112 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 25 mg · wk 8 · n 123 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.2% 25 mg QD · wk 8 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.2% 25 mg QD · wk 8 · n 201 · Phase 3 · secondary NCT00286442
  • -0.6% vs -0.3% 25 mg QD · wk 4 · n 116 · Phase 3 · secondary NCT00286429
  • -0.5% vs -0.1% 25 mg QD · wk 4 · n 120 · Phase 3 · secondary NCT00286455
  • -0.3% vs 0.1% 25 mg QD · wk 4 · n 112 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 25 mg · wk 4 · n 110 · Phase 3 · secondary NCT00328627
  • -0.5% vs -0.1% 25 mg QD · wk 4 · n 176 · Phase 3 · secondary NCT00286494
  • -0.4% vs -0.1% 25 mg QD · wk 4 · n 187 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.2% 12.5 mg QD · wk 20 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 20 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 20 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.2% 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.3% 12.5 mg QD · wk 20 · n 196 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 12.5 mg QD · wk 20 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.2% 12.5 mg QD · wk 16 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 16 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 16 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 16 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.3% 12.5 mg QD · wk 16 · n 196 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.1% 12.5 mg QD · wk 16 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 12.5 mg QD · wk 12 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 12 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 12 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.2% 12.5 mg QD · wk 12 · n 196 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.2% 12.5 mg QD · wk 12 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 12.5 mg QD · wk 8 · n 130 · Phase 3 · secondary NCT00286429
  • -0.5% vs -0.1% 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 8 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg QD · wk 8 · n 196 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.2% 12.5 mg QD · wk 8 · n 210 · Phase 3 · secondary NCT00286442
  • -0.5% vs -0.3% 12.5 mg QD · wk 4 · n 116 · Phase 3 · secondary NCT00286429
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 123 · Phase 3 · secondary NCT00286455
  • -0.4% vs 0.1% 12.5 mg BID · wk 4 · n 110 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 12.5 mg · wk 4 · n 114 · Phase 3 · secondary NCT00328627
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 182 · Phase 3 · secondary NCT00286494
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 188 · Phase 3 · secondary NCT00286442
  • -1.4% vs -0.2% 25 mg + 15 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.2% 25 mg + 30 mg · wk 20 · n 124 · Phase 3 · secondary NCT00328627
  • -1.7% vs -0.2% 25 mg + 45 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 25 mg + 15 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 25 mg + 30 mg · wk 16 · n 124 · Phase 3 · secondary NCT00328627
  • -1.7% vs -0.3% 25 mg + 45 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 25 mg + 15 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 25 mg + 30 mg · wk 12 · n 124 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.3% 25 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.3% 25 mg + 15 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.3% 25 mg + 30 mg · wk 8 · n 124 · Phase 3 · secondary NCT00328627
  • -1.2% vs -0.3% 25 mg + 45 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 15 mg · wk 4 · n 116 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 30 mg · wk 4 · n 118 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 45 mg · wk 4 · n 112 · Phase 3 · secondary NCT00328627
  • -1.3% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 20 · n 106 · Phase 3 · secondary NCT01023581
  • -1.5% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 20 · n 114 · Phase 3 · secondary NCT01023581
  • -1.4% vs -0.2% 12.5 mg + 15 mg · wk 20 · n 130 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.2% 12.5 mg + 30 mg · wk 20 · n 128 · Phase 3 · secondary NCT00328627
  • -1.6% vs -0.2% 12.5 mg + 45 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -1.3% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 16 · n 106 · Phase 3 · secondary NCT01023581
  • -1.5% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 16 · n 114 · Phase 3 · secondary NCT01023581
  • -1.4% vs -0.3% 12.5 mg + 15 mg · wk 16 · n 130 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 12.5 mg + 30 mg · wk 16 · n 128 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.3% 12.5 mg + 45 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 12 · n 106 · Phase 3 · secondary NCT01023581
  • -1.4% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 12 · n 114 · Phase 3 · secondary NCT01023581
  • -1.2% vs -0.3% 12.5 mg + 15 mg · wk 12 · n 130 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 12.5 mg + 30 mg · wk 12 · n 128 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 12.5 mg + 45 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -1.1% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 8 · n 106 · Phase 3 · secondary NCT01023581
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 8 · n 114 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.3% 12.5 mg + 15 mg · wk 8 · n 130 · Phase 3 · secondary NCT00328627
  • -1.1% vs -0.3% 12.5 mg + 30 mg · wk 8 · n 128 · Phase 3 · secondary NCT00328627
  • -1.1% vs -0.3% 12.5 mg + 45 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -0.7% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 4 · n 106 · Phase 3 · secondary NCT01023581
  • -0.8% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 4 · n 114 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 12.5 mg + 15 mg · wk 4 · n 120 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg + 30 mg · wk 4 · n 122 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg + 45 mg · wk 4 · n 117 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.4% wk 12 · n 92 · Phase 3 · secondary NCT01289119
  • -0.9% vs -0.4% wk 12 · n 99 · Phase 3 · secondary NCT01289119
  • -0.8% vs -0.4% wk 12 · n 61 · Phase 3 · secondary NCT01289119
  • -0.9% vs -0.4% wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -0.7% vs -0.4% wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.7% vs -0.4% wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.6% vs -0.2% wk 4 · n 92 · Phase 3 · secondary NCT01289119
  • -0.4% vs -0.2% wk 4 · n 99 · Phase 3 · secondary NCT01289119
  • -0.4% vs -0.2% wk 4 · n 61 · Phase 3 · secondary NCT01289119
  • -1% vs -1.2% 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0% vs -1.2% 25 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0% vs -1.0% 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.7% 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -0.6% vs -0.3% 25 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.7% 25 mg · wk 39 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 25 mg · wk 65 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 34 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.8% 25 mg · wk 26 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 25 mg · wk 78 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 25 mg · wk 20 · n 382 · Phase 3 · secondary NCT00856284
  • -0.9% vs -0.5% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 20 · n 303 · Phase 3 · secondary NCT00432276
  • -0.7% vs -0.0% 12.5 mg QD · wk 8 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.4% vs -0.0% 12.5 mg QD · wk 4 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.2% vs -0.0% 12.5 mg QD · wk 2 · n 76 · Phase 2/3 · secondary NCT01263483
  • -1.7% vs -1.2% 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.8% 25 mg · wk 16 · n 382 · Phase 3 · secondary NCT00856284
  • -0.9% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 16 · n 303 · Phase 3 · secondary NCT00432276
  • -1.7% vs -1.2% 25 mg + 30 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.7% 25 mg · wk 91 · n 382 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.8% 25 mg · wk 12 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 303 · Phase 3 · secondary NCT00432276
  • -1.6% vs -1.0% 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.6% vs -0.7% 25 mg · wk 8 · n 382 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 303 · Phase 3 · secondary NCT00432276
  • -1.2% vs -0.7% 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -0.4% vs -0.4% 25 mg · wk 4 · n 382 · Phase 3 · secondary NCT00856284
  • -0.6% vs 0.2% 25 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8% vs -0.2% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.4% vs -0.1% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.0% 25 mg QD + 0.2 mg TID · wk 8 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.6% vs -0.3% 25 mg + 30 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.7% 12.5 mg · wk 39 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 65 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 26 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 12.5 mg · wk 78 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 20 · n 371 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.8% 12.5 mg · wk 16 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 12.5 mg · wk 91 · n 371 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.8% 12.5 mg · wk 12 · n 371 · Phase 3 · secondary NCT00856284
  • -0.6% vs -0.7% 12.5 mg · wk 8 · n 371 · Phase 3 · secondary NCT00856284
  • -0.4% vs -0.4% 12.5 mg · wk 4 · n 371 · Phase 3 · secondary NCT00856284
  • -0.4% vs 0.1% 25 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.5% vs -0.1% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.4% vs -0.0% 25 mg QD + 0.2 mg TID · wk 4 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.1% vs 0.1% 25 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.2% vs -0.0% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.2% vs -0.0% 25 mg QD + 0.2 mg TID · wk 2 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.5% vs -1.2% 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • -1.4% vs -1.2% 12.5 mg + 30 mg · wk 16 · n 163 · Phase 3 · secondary NCT00395512
  • -1.3% vs -1.0% 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • -1.0% vs -0.7% 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
  • -0.5% vs 0.2% 12.5 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8% vs -0.2% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.5% vs -0.3% 12.5 mg + 30 mg · wk 4 · n 163 · Phase 3 · secondary NCT00395512
  • -0.3% vs 0.1% 12.5 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.5% vs -0.1% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.1% vs 0.1% 12.5 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.2% vs -0.0% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 110 · Phase 2/3 · secondary NCT01318070
  • -0.6% vs -0.0% 25 mg QD · wk 12.14 · n 45 · Phase 2 · primary NCT00755846
  • -0.8% vs 0.1% 25 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.5% vs -0.0% 12.5 mg QD · wk 12.14 · n 42 · Phase 2 · primary NCT00755846
  • -0.7% vs 0.1% 12.5 mg QD · wk 12 · n 84 · Phase 2 · primary NCT01263470
  • -0.5% vs -0.0% 100 mg QD · wk 12.14 · n 44 · Phase 2 · primary NCT00755846
  • -0.4% vs -0.0% 50 mg QD · wk 12.14 · n 43 · Phase 2 · primary NCT00755846
  • -0.8% vs 0.1% 50 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.2% vs -0.0% 6.25 mg QD · wk 12.14 · n 42 · Phase 2 · primary NCT00755846
  • -0.5% vs 0.1% 6.25 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.7% vs 0% 25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4% vs 0.0% 25 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.3% vs -0.0% 25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.6% vs 0% 12.5 mg QD · wk 8 · n 84 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 12.5 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.4% vs -0.0% 12.5 mg QD · wk 4 · n 84 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 12.5 mg QD · wk 2 · n 84 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 100 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.7% vs 0% 50 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 50 mg QD · wk 6.14 · n 43 · Phase 2 · secondary NCT00755846
  • -0.4% vs -0.0% 50 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.1% vs 0% 50 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.5% vs 0% 6.25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.1% vs 0.0% 6.25 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.3% vs -0.0% 6.25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 6.25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.7% vs -0.4% 25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 44 · n 63 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 25 mg QD · wk 32 · n 87 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 28 · n 87 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 20 · n 88 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 25 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.1% 25 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.2% 25 mg QD · n 96 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.4% 12.5 mg QD · wk 52 · n 59 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.4% 12.5 mg QD · wk 48 · n 60 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 44 · n 61 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 12.5 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 12.5 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 32 · n 81 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 28 · n 82 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 24 · n 84 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 12.5 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 12.5 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.1% 12.5 mg QD · wk 12 · n 97 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.2% 12.5 mg QD · n 101 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 50 mg QD · wk 52 · n 68 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 50 mg QD · wk 48 · n 69 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 44 · n 69 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 40 · n 84 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 36 · n 84 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 32 · n 85 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 28 · n 86 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.3% 50 mg QD · wk 20 · n 90 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.3% 50 mg QD · wk 16 · n 91 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.1% 50 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.2% 50 mg QD · n 97 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.4% 6.25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.4% 6.25 mg QD · wk 48 · n 63 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 44 · n 65 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 40 · n 81 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 32 · n 84 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.3% 6.25 mg QD · wk 28 · n 85 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 6.25 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 6.25 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 6.25 mg QD · wk 16 · n 88 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.1% 6.25 mg QD · wk 12 · n 93 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.2% 6.25 mg QD · n 96 · Phase 2 · secondary NCT01263496
-0.7% vs -0.3%−0.4 vs placebo5 mg · wk 24 · n 300NCT00757588
19 other results
  • 7.1% vs 7.5% 5 mg · wk 24 · n 275 · Phase 3 · primary NCT00661362
  • -0.5% vs -0.2% 5 mg · wk 24 · n 139 · Phase 3 · primary NCT01619059
  • 0.1% vs 0.5% wk 26 · n 82 · Phase 3 · primary NCT03199053
  • -0.8% vs -0.1% wk 24 · n 158 · Phase 3 · primary NCT01646320
  • -0.7% vs -0.1% wk 24 · n 127 · Phase 3 · primary NCT01128153
  • -0.7% vs 0.6% wk 16 · n 4 · Phase 3 · primary NCT01204775
  • -1% vs 0.9% wk 16 · n 4 · Phase 3 · primary NCT01434186
  • -1.4% vs -1.0% dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 218 · Phase 3 · primary NCT02419612
  • -1.4% vs -1.1% wk 26 · n 224 · Phase 3 · primary NCT02284893
  • -1.7% vs -1.5% wk 24 · n 319 · Phase 3 · primary NCT02551874
  • -1.0% vs -0.7% wk 24 · n 290 · Phase 3 · primary NCT02681094
  • -0.2% vs -0.7% 5 mg · wk 26 · n 25 · Phase 3 · secondary NCT03199053
  • 0.1% vs -0.7% 2.5 mg · wk 26 · n 24 · Phase 3 · secondary NCT03199053
  • -0.8% vs -1.0% 10mg · wk 52 · n 311 · Phase 4 · primary NCT02471404
  • -1.2% vs -1.0% 5mg and 10mg · wk 52 · n 312 · Phase 4 · primary NCT02471404
  • -0.8% vs -0.8% wk 24 · n 238 · Phase 4 · primary NCT02243176
  • -0.8% vs -0.8% wk 24 · n 219 · Phase 4 · primary NCT02243176
  • -0.5% vs -0.4% wk 24 · n 146 · Phase 4 · primary NCT01006590
  • -0.4% vs -0.6% 5 mg · wk 52 · n 353 · Phase 4 · secondary NCT01006603
Body weight, change (kg)0.6 vs 0.6±0 vs placebo25 mg QD · wk 26 · n 124NCT00286429
111 other results
  • -0.2 vs 0.2 25 mg QD · wk 26 · n 125 · Phase 3 · secondary NCT00286455
  • -0.7 vs -0.7 25 mg · wk 26 · n 123 · Phase 3 · secondary NCT00328627
  • 1.1 vs 1.0 25 mg QD · wk 26 · n 189 · Phase 3 · secondary NCT00286494
  • -0.7 vs -0.4 25 mg QD · wk 26 · n 198 · Phase 3 · secondary NCT00286442
  • 0.7 vs -0.2 25 mg QD · wk 26 · n 195 · Phase 3 · secondary NCT00286468
  • 0.5 vs 0.7 25 mg QD · wk 20 · n 124 · Phase 3 · secondary NCT00286429
  • -0.2 vs -0.2 25 mg QD · wk 20 · n 125 · Phase 3 · secondary NCT00286455
  • -0.5 vs -0.6 25 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • 0.9 vs 0.9 25 mg QD · wk 20 · n 189 · Phase 3 · secondary NCT00286494
  • -0.6 vs -0.4 25 mg QD · wk 20 · n 198 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.3 25 mg QD · wk 20 · n 195 · Phase 3 · secondary NCT00286468
  • 0.3 vs 0.5 25 mg QD · wk 12 · n 123 · Phase 3 · secondary NCT00286429
  • 0.1 vs -0.3 25 mg QD · wk 12 · n 125 · Phase 3 · secondary NCT00286455
  • -0.6 vs -0.5 25 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • 0.6 vs 0.6 25 mg QD · wk 12 · n 189 · Phase 3 · secondary NCT00286494
  • -0.6 vs -0.6 25 mg QD · wk 12 · n 198 · Phase 3 · secondary NCT00286442
  • 0.4 vs -0.1 25 mg QD · wk 12 · n 194 · Phase 3 · secondary NCT00286468
  • 0.2 vs 0.4 25 mg QD · wk 8 · n 121 · Phase 3 · secondary NCT00286429
  • -0.0 vs -0.4 25 mg QD · wk 8 · n 123 · Phase 3 · secondary NCT00286455
  • -0.5 vs -0.1 25 mg · wk 8 · n 120 · Phase 3 · secondary NCT00328627
  • 0.4 vs 0.4 25 mg QD · wk 8 · n 186 · Phase 3 · secondary NCT00286494
  • -0.5 vs -0.1 25 mg QD · wk 8 · n 193 · Phase 3 · secondary NCT00286442
  • 0.3 vs -0.3 25 mg QD · wk 8 · n 188 · Phase 3 · secondary NCT00286468
  • 0.7 vs 0.6 12.5 mg QD · wk 26 · n 127 · Phase 3 · secondary NCT00286429
  • -0.1 vs 0.2 12.5 mg QD · wk 26 · n 126 · Phase 3 · secondary NCT00286455
  • -0.0 vs -0.7 12.5 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • 1.5 vs 1.0 12.5 mg QD · wk 26 · n 193 · Phase 3 · secondary NCT00286494
  • -0.4 vs -0.4 12.5 mg QD · wk 26 · n 206 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.2 12.5 mg QD · wk 26 · n 197 · Phase 3 · secondary NCT00286468
  • 0.6 vs 0.7 12.5 mg QD · wk 20 · n 127 · Phase 3 · secondary NCT00286429
  • -0.2 vs -0.2 12.5 mg QD · wk 20 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.6 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • 1.1 vs 0.9 12.5 mg QD · wk 20 · n 193 · Phase 3 · secondary NCT00286494
  • -0.4 vs -0.4 12.5 mg QD · wk 20 · n 205 · Phase 3 · secondary NCT00286442
  • 0.8 vs -0.3 12.5 mg QD · wk 20 · n 197 · Phase 3 · secondary NCT00286468
  • 0.4 vs 0.5 12.5 mg QD · wk 12 · n 127 · Phase 3 · secondary NCT00286429
  • -0.4 vs -0.3 12.5 mg QD · wk 12 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.5 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • 0.7 vs 0.6 12.5 mg QD · wk 12 · n 193 · Phase 3 · secondary NCT00286494
  • -0.3 vs -0.6 12.5 mg QD · wk 12 · n 205 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.1 12.5 mg QD · wk 12 · n 197 · Phase 3 · secondary NCT00286468
  • 0.1 vs 0.4 12.5 mg QD · wk 8 · n 125 · Phase 3 · secondary NCT00286429
  • 0.0 vs -0.4 12.5 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.1 12.5 mg · wk 8 · n 119 · Phase 3 · secondary NCT00328627
  • 0.5 vs 0.4 12.5 mg QD · wk 8 · n 190 · Phase 3 · secondary NCT00286494
  • -0.3 vs -0.1 12.5 mg QD · wk 8 · n 198 · Phase 3 · secondary NCT00286442
  • 0.5 vs -0.3 12.5 mg QD · wk 8 · n 194 · Phase 3 · secondary NCT00286468
  • 1.3 vs -0.7 25 mg + 15 mg · wk 26 · n 124 · Phase 3 · secondary NCT00328627
  • 2.1 vs -0.7 25 mg + 30 mg · wk 26 · n 123 · Phase 3 · secondary NCT00328627
  • 2.3 vs -0.7 25 mg + 45 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • 0.8 vs -0.6 25 mg + 15 mg · wk 20 · n 124 · Phase 3 · secondary NCT00328627
  • 1.8 vs -0.6 25 mg + 30 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • 1.8 vs -0.6 25 mg + 45 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • 0.4 vs -0.5 25 mg + 15 mg · wk 12 · n 124 · Phase 3 · secondary NCT00328627
  • 1.0 vs -0.5 25 mg + 30 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • 1.1 vs -0.5 25 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • 0.2 vs -0.1 25 mg + 15 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • 0.7 vs -0.1 25 mg + 30 mg · wk 8 · n 121 · Phase 3 · secondary NCT00328627
  • 0.9 vs -0.1 25 mg + 45 mg · wk 8 · n 124 · Phase 3 · secondary NCT00328627
  • 1.3 vs -0.7 12.5 mg + 15 mg · wk 26 · n 127 · Phase 3 · secondary NCT00328627
  • 1.9 vs -0.7 12.5 mg + 30 mg · wk 26 · n 125 · Phase 3 · secondary NCT00328627
  • 2.3 vs -0.7 12.5 mg + 45 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • 1.0 vs -0.6 12.5 mg + 15 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • 1.4 vs -0.6 12.5 mg + 30 mg · wk 20 · n 125 · Phase 3 · secondary NCT00328627
  • 1.9 vs -0.6 12.5 mg + 45 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • 0.2 vs -0.5 12.5 mg + 15 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • 0.6 vs -0.5 12.5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT00328627
  • 0.9 vs -0.5 12.5 mg + 45 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • 0.1 vs -0.1 12.5 mg + 15 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • 0.5 vs -0.1 12.5 mg + 30 mg · wk 8 · n 125 · Phase 3 · secondary NCT00328627
  • 0.4 vs -0.1 12.5 mg + 45 mg · wk 8 · n 121 · Phase 3 · secondary NCT00328627
  • -0.9 vs -1.6 wk 16 · n 92 · Phase 3 · secondary NCT01289119
  • -0.8 vs -1.6 wk 16 · n 99 · Phase 3 · secondary NCT01289119
  • -0.1 vs -1.6 wk 16 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7 vs -1.0 wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -0.4 vs -1.0 wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.1 vs -1.0 wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.9 vs 0.9 25 mg · wk 52 · n 868 · Phase 3 · secondary NCT00856284
  • 1.1 vs 1.6 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 404 · Phase 3 · secondary NCT00432276
  • 1.1 vs 1.5 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs 1.0 25 mg · wk 39 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 65 · n 868 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 25 mg · wk 26 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 78 · n 868 · Phase 3 · secondary NCT00856284
  • 0.7 vs 1.0 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs 0.9 25 mg · wk 91 · n 868 · Phase 3 · secondary NCT00856284
  • -0.5 vs 0.7 25 mg · wk 12 · n 868 · Phase 3 · secondary NCT00856284
  • 0.3 vs 0.6 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 404 · Phase 3 · secondary NCT00432276
  • 0.3 vs 0.5 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 404 · Phase 3 · secondary NCT00432276
  • 0.2 vs 0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs 0.9 25 mg · wk 104 · n 868 · Phase 3 · secondary NCT00856284
  • -0.6 vs 0.9 12.5 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs 1.0 12.5 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.8 vs 0.9 12.5 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs 0.7 12.5 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 2.2 25 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -0.5 vs 1.6 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8 vs 1.0 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.3 vs 0.6 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • 3.1 vs 2.2 25 mg + 30 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • 2.4 vs 1.6 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • 1.4 vs 1.0 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • 0.8 vs 0.6 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • 2.5 vs 2.2 12.5 mg + 30 mg · wk 26 · n 163 · Phase 3 · secondary NCT00395512
  • 1.9 vs 1.6 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • 1.2 vs 1.0 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • 0.7 vs 0.6 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
-1.9 vs -0.4−1.5 vs placebowk 24 · n 158NCT01646320
7 other results
  • -3.1 vs 0.9 dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 224 · Phase 3 · secondary NCT02419612
  • -1.9 vs -0.5 wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • -1.5 vs 2.1 wk 24 · n 319 · Phase 3 · secondary NCT02551874
  • -2.0 vs -0.4 wk 24 · n 290 · Phase 3 · secondary NCT02681094
  • -3.5 vs 1.8 10mg · wk 52 · n 311 · Phase 4 · secondary NCT02471404
  • -3.1 vs 1.8 5mg and 10mg · wk 52 · n 312 · Phase 4 · secondary NCT02471404
  • -1.4 vs -2.0 wk 24 · n 238 · Phase 4 · secondary NCT02243176
HbA1c below 7%63.3% vs 30%+33.3 vs placebowk 16 · n 90NCT01289119
2 other results
  • 55.1% vs 30% wk 16 · n 98 · Phase 3 · secondary NCT01289119
  • 61.7% vs 30% wk 16 · n 60 · Phase 3 · secondary NCT01289119
44.4% vs 16.6%+27.8 vs placebo10 mg · wk 24 · n 180NCT00121667
15 other results
  • 41.1% vs 23.9% 10 mg · wk 24 · n 95 · Phase 3 · secondary NCT00121641
  • 43.5% vs 16.6% 5 mg · wk 24 · n 186 · Phase 3 · secondary NCT00121667
  • 37.9% vs 23.9% 5 mg · wk 24 · n 103 · Phase 3 · secondary NCT00121641
  • 22.1% vs 13.3% 5 mg · wk 24 · n 104 · Phase 3 · secondary NCT00918879
  • 45.8% vs 28.8% 5 mg · wk 24 · n 277 · Phase 3 · secondary NCT00698932
  • 37.1% vs 16.6% 2.5 mg · wk 24 · n 186 · Phase 3 · secondary NCT00121667
  • 35% vs 23.9% 2.5 mg · wk 24 · n 100 · Phase 3 · secondary NCT00121641
  • 37.5% vs 24.2% 2.5 mg · wk 12 · n 73 · Phase 3 · secondary NCT00885378
  • 21.3% vs 10% wk 26 · n 61 · Phase 3 · secondary NCT03199053
  • 36.7% vs 13.3% wk 24 · n 158 · Phase 3 · secondary NCT01646320
  • 21.4% vs 11.7% dapagliflozin 10 mg, saxagliptin 5 mg · wk 156 · n 227 · Phase 3 · secondary NCT02419612
  • 44.3% vs 34.3% dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 227 · Phase 3 · secondary NCT02419612
  • 37.3% vs 25.1% wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • 37.2% vs 26.1% wk 18 · n 137 · Phase 3 · secondary NCT00960076
  • 38.3% vs 41.5% wk 24 · n 230 · Phase 4 · secondary NCT02243176
Fasting plasma glucose, change-0.7 vs 0.3−1 vs placebo25 mg QD · wk 26 · n 128NCT00286429
351 other results
  • -0.9 vs 0.6 25 mg QD · wk 26 · n 131 · Phase 3 · secondary NCT00286455
  • -0.3 vs 0.7 25 mg QD · wk 26 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0 vs 0.4 25 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.3 25 mg QD · wk 26 · n 197 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0 25 mg QD · wk 26 · n 204 · Phase 3 · secondary NCT00286442
  • -0.5 vs 0.1 25 mg QD · wk 26 · n 198 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.5 25 mg QD · wk 20 · n 128 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.4 25 mg QD · wk 20 · n 129 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.5 25 mg QD · wk 20 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.4 25 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.4 25 mg QD · wk 20 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs -0.0 25 mg QD · wk 20 · n 204 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.0 25 mg QD · wk 20 · n 198 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 25 mg QD · wk 16 · n 128 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.3 25 mg QD · wk 16 · n 129 · Phase 3 · secondary NCT00286455
  • -0.4 vs 0.6 25 mg QD · wk 16 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.1 25 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.5 25 mg QD · wk 16 · n 197 · Phase 3 · secondary NCT00286494
  • -0.8 vs 0.1 25 mg QD · wk 16 · n 204 · Phase 3 · secondary NCT00286442
  • -0.7 vs -0.4 25 mg QD · wk 16 · n 198 · Phase 3 · secondary NCT00286468
  • -0.2 vs -0.1 25 mg QD · wk 12 · n 128 · Phase 3 · secondary NCT00286429
  • -1.1 vs 0.1 25 mg QD · wk 12 · n 129 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.6 25 mg QD · wk 12 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.2 25 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -1.4 vs -0.6 25 mg QD · wk 12 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 25 mg QD · wk 12 · n 204 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 25 mg QD · wk 12 · n 198 · Phase 3 · secondary NCT00286468
  • -0.8 vs 0.3 25 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286429
  • -1.1 vs 0.1 25 mg QD · wk 8 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.4 25 mg QD · wk 8 · n 112 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 25 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -1.5 vs -0.3 25 mg QD · wk 8 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 25 mg QD · wk 8 · n 204 · Phase 3 · secondary NCT00286442
  • -1.0 vs -0.2 25 mg QD · wk 8 · n 198 · Phase 3 · secondary NCT00286468
  • -0.7 vs 0.3 25 mg QD · wk 4 · n 120 · Phase 3 · secondary NCT00286429
  • -1.2 vs 0.2 25 mg QD · wk 4 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.4 25 mg QD · wk 4 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.2 25 mg · wk 4 · n 125 · Phase 3 · secondary NCT00328627
  • -1.4 vs -0.2 25 mg QD · wk 4 · n 197 · Phase 3 · secondary NCT00286494
  • -1 vs -0.0 25 mg QD · wk 4 · n 204 · Phase 3 · secondary NCT00286442
  • -1.2 vs -0.2 25 mg QD · wk 4 · n 197 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.1 25 mg QD · wk 2 · n 119 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.2 25 mg QD · wk 2 · n 126 · Phase 3 · secondary NCT00286455
  • -0.4 vs 0.3 25 mg QD · wk 2 · n 112 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 25 mg · wk 2 · n 125 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.1 25 mg QD · wk 2 · n 193 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 25 mg QD · wk 2 · n 199 · Phase 3 · secondary NCT00286442
  • -1.2 vs -0.1 25 mg QD · wk 2 · n 194 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.3 25 mg QD · wk 1 · n 111 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.3 25 mg QD · wk 1 · n 121 · Phase 3 · secondary NCT00286455
  • -0.2 vs 0.3 25 mg QD · wk 1 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0 vs 0.1 25 mg · wk 1 · n 117 · Phase 3 · secondary NCT00328627
  • -1.0 vs -0.1 25 mg QD · wk 1 · n 171 · Phase 3 · secondary NCT00286494
  • -0.7 vs -0.0 25 mg QD · wk 1 · n 186 · Phase 3 · secondary NCT00286442
  • -1.1 vs 0.0 25 mg QD · wk 1 · n 185 · Phase 3 · secondary NCT00286468
  • 0.1 vs 0.3 12.5 mg QD · wk 26 · n 131 · Phase 3 · secondary NCT00286429
  • -0.6 vs 0.6 12.5 mg QD · wk 26 · n 132 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.7 12.5 mg BID · wk 26 · n 110 · Phase 3 · secondary NCT01023581
  • -0.7 vs 0.4 12.5 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.3 12.5 mg QD · wk 26 · n 196 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0 12.5 mg QD · wk 26 · n 211 · Phase 3 · secondary NCT00286442
  • -0.3 vs 0.1 12.5 mg QD · wk 26 · n 201 · Phase 3 · secondary NCT00286468
  • -0.2 vs 0.5 12.5 mg QD · wk 20 · n 131 · Phase 3 · secondary NCT00286429
  • -0.7 vs 0.4 12.5 mg QD · wk 20 · n 132 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.5 12.5 mg BID · wk 20 · n 110 · Phase 3 · secondary NCT01023581
  • -0.5 vs 0.4 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.4 12.5 mg QD · wk 20 · n 196 · Phase 3 · secondary NCT00286494
  • -1 vs -0.0 12.5 mg QD · wk 20 · n 211 · Phase 3 · secondary NCT00286442
  • -0.5 vs -0.0 12.5 mg QD · wk 20 · n 201 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 16 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.3 12.5 mg QD · wk 16 · n 132 · Phase 3 · secondary NCT00286455
  • -0.8 vs 0.6 12.5 mg BID · wk 16 · n 110 · Phase 3 · secondary NCT01023581
  • -0.9 vs 0.1 12.5 mg · wk 16 · n 122 · Phase 3 · secondary NCT00328627
  • -1.0 vs -0.5 12.5 mg QD · wk 16 · n 196 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0.1 12.5 mg QD · wk 16 · n 211 · Phase 3 · secondary NCT00286442
  • -0.5 vs -0.4 12.5 mg QD · wk 16 · n 201 · Phase 3 · secondary NCT00286468
  • -0.3 vs -0.1 12.5 mg QD · wk 12 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.1 12.5 mg QD · wk 12 · n 132 · Phase 3 · secondary NCT00286455
  • -0.8 vs 0.6 12.5 mg BID · wk 12 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.2 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.6 12.5 mg QD · wk 12 · n 196 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 12.5 mg QD · wk 12 · n 211 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 12.5 mg QD · wk 12 · n 201 · Phase 3 · secondary NCT00286468
  • -0.8 vs 0.3 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.1 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.4 12.5 mg BID · wk 8 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 12.5 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.3 12.5 mg QD · wk 8 · n 196 · Phase 3 · secondary NCT00286494
  • -1.1 vs 0.0 12.5 mg QD · wk 8 · n 211 · Phase 3 · secondary NCT00286442
  • -1.1 vs -0.2 12.5 mg QD · wk 8 · n 200 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 4 · n 128 · Phase 3 · secondary NCT00286429
  • -0.9 vs 0.2 12.5 mg QD · wk 4 · n 131 · Phase 3 · secondary NCT00286455
  • -0.9 vs 0.4 12.5 mg BID · wk 4 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.2 12.5 mg · wk 4 · n 122 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.2 12.5 mg QD · wk 4 · n 194 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 12.5 mg QD · wk 4 · n 211 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 12.5 mg QD · wk 4 · n 198 · Phase 3 · secondary NCT00286468
  • -0.2 vs 0.1 12.5 mg QD · wk 2 · n 127 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.2 12.5 mg QD · wk 2 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.3 12.5 mg BID · wk 2 · n 110 · Phase 3 · secondary NCT01023581
  • -1.2 vs 0.3 12.5 mg · wk 2 · n 120 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.1 12.5 mg QD · wk 2 · n 189 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 12.5 mg QD · wk 2 · n 208 · Phase 3 · secondary NCT00286442
  • -0.9 vs -0.1 12.5 mg QD · wk 2 · n 197 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 1 · n 121 · Phase 3 · secondary NCT00286429
  • -0.5 vs 0.3 12.5 mg QD · wk 1 · n 120 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.3 12.5 mg BID · wk 1 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8 vs 0.1 12.5 mg · wk 1 · n 114 · Phase 3 · secondary NCT00328627
  • -0.8 vs -0.1 12.5 mg QD · wk 1 · n 176 · Phase 3 · secondary NCT00286494
  • -0.8 vs -0.0 12.5 mg QD · wk 1 · n 193 · Phase 3 · secondary NCT00286442
  • -0.7 vs 0.0 12.5 mg QD · wk 1 · n 189 · Phase 3 · secondary NCT00286468
  • -2.1 vs 0.4 25 mg + 15 mg · wk 26 · n 130 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 25 mg + 30 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 25 mg + 45 mg · wk 26 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.4 25 mg + 15 mg · wk 20 · n 130 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.4 25 mg + 30 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 25 mg + 45 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.1 25 mg + 15 mg · wk 16 · n 130 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.1 25 mg + 30 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -3.0 vs 0.1 25 mg + 45 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.2 25 mg + 15 mg · wk 12 · n 130 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.2 25 mg + 30 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.2 25 mg + 45 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.3 25 mg + 15 mg · wk 8 · n 130 · Phase 3 · secondary NCT00328627
  • -2.5 vs 0.3 25 mg + 30 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.3 25 mg + 45 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 25 mg + 15 mg · wk 4 · n 130 · Phase 3 · secondary NCT00328627
  • -2 vs 0.2 25 mg + 30 mg · wk 4 · n 126 · Phase 3 · secondary NCT00328627
  • -2.6 vs 0.2 25 mg + 45 mg · wk 4 · n 127 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 25 mg + 15 mg · wk 2 · n 129 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 25 mg + 30 mg · wk 2 · n 126 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 25 mg + 45 mg · wk 2 · n 126 · Phase 3 · secondary NCT00328627
  • -1.2 vs 0.1 25 mg + 15 mg · wk 1 · n 123 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 25 mg + 30 mg · wk 1 · n 118 · Phase 3 · secondary NCT00328627
  • -1.4 vs 0.1 25 mg + 45 mg · wk 1 · n 113 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.7 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 26 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.7 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 26 · n 114 · Phase 3 · secondary NCT01023581
  • -2.3 vs 0.4 12.5 mg + 15 mg · wk 26 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 12.5 mg + 30 mg · wk 26 · n 129 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 12.5 mg + 45 mg · wk 26 · n 128 · Phase 3 · secondary NCT00328627
  • -1.9 vs 0.5 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 20 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.5 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 20 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.4 12.5 mg + 15 mg · wk 20 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 12.5 mg + 30 mg · wk 20 · n 129 · Phase 3 · secondary NCT00328627
  • -2.6 vs 0.4 12.5 mg + 45 mg · wk 20 · n 128 · Phase 3 · secondary NCT00328627
  • -2.0 vs 0.6 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 16 · n 106 · Phase 3 · secondary NCT01023581
  • -2.6 vs 0.6 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 16 · n 114 · Phase 3 · secondary NCT01023581
  • -2.3 vs 0.1 12.5 mg + 15 mg · wk 16 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.1 12.5 mg + 30 mg · wk 16 · n 129 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.1 12.5 mg + 45 mg · wk 16 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.6 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 12 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.6 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 12 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.2 12.5 mg + 15 mg · wk 12 · n 129 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.2 12.5 mg + 30 mg · wk 12 · n 129 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.2 12.5 mg + 45 mg · wk 12 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.4 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 8 · n 106 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.4 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 8 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.3 12.5 mg + 15 mg · wk 8 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.3 12.5 mg + 30 mg · wk 8 · n 129 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.3 12.5 mg + 45 mg · wk 8 · n 128 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.4 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 4 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.4 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 4 · n 114 · Phase 3 · secondary NCT01023581
  • -2.0 vs 0.2 12.5 mg + 15 mg · wk 4 · n 129 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 12.5 mg + 30 mg · wk 4 · n 129 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 12.5 mg + 45 mg · wk 4 · n 128 · Phase 3 · secondary NCT00328627
  • -1.9 vs 0.3 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 2 · n 106 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.3 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 2 · n 114 · Phase 3 · secondary NCT01023581
  • -1.7 vs 0.3 12.5 mg + 15 mg · wk 2 · n 127 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 12.5 mg + 30 mg · wk 2 · n 128 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 12.5 mg + 45 mg · wk 2 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 1 · n 106 · Phase 3 · secondary NCT01023581
  • -2.0 vs 0.3 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 1 · n 114 · Phase 3 · secondary NCT01023581
  • -1.2 vs 0.1 12.5 mg + 15 mg · wk 1 · n 121 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 12.5 mg + 30 mg · wk 1 · n 119 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 12.5 mg + 45 mg · wk 1 · n 115 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.3 wk 16 · n 92 · Phase 3 · secondary NCT01289119
  • -1.2 vs -0.3 wk 16 · n 99 · Phase 3 · secondary NCT01289119
  • -0.9 vs 0.7 25 mg QD · wk 16 · n 25 · Phase 3 · secondary NCT00655863
  • -0.9 vs 0.3 25 mg QD · wk 8 · n 25 · Phase 3 · secondary NCT00655863
  • -1.1 vs -0.2 25 mg QD · wk 4 · n 25 · Phase 3 · secondary NCT00655863
  • -2.1 vs 0.7 25 mg QD + 30 mg QD · wk 16 · n 22 · Phase 3 · secondary NCT00655863
  • -2.1 vs 0.3 25 mg QD + 30 mg QD · wk 8 · n 22 · Phase 3 · secondary NCT00655863
  • -2.2 vs -0.2 25 mg QD + 30 mg QD · wk 4 · n 22 · Phase 3 · secondary NCT00655863
  • -1.1 vs -0.3 wk 16 · n 61 · Phase 3 · secondary NCT01289119
  • -1.1 vs -0.4 wk 12 · n 92 · Phase 3 · secondary NCT01289119
  • -1.3 vs -0.4 wk 12 · n 99 · Phase 3 · secondary NCT01289119
  • -1.2 vs -0.4 wk 12 · n 61 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -1.3 vs -0.3 wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.9 vs -0.3 wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7 vs -0.3 wk 4 · n 92 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 4 · n 99 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 4 · n 61 · Phase 3 · secondary NCT01289119
  • -0.4 vs 0.1 25 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.8 vs -0.2 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 404 · Phase 3 · secondary NCT00432276
  • -0.5 vs -0.0 25 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 0.1 25 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.8 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 34 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.2 25 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 0.3 25 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.3 25 mg · wk 20 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 20 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.4 25 mg · wk 16 · n 867 · Phase 3 · secondary NCT00856284
  • -1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 16 · n 404 · Phase 3 · secondary NCT00432276
  • -0.2 vs 0.3 25 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.5 25 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -1.1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.5 25 mg · wk 8 · n 867 · Phase 3 · secondary NCT00856284
  • -1.1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.6 25 mg · wk 4 · n 867 · Phase 3 · secondary NCT00856284
  • -1.0 vs -0.1 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.4 25 mg · wk 2 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.0 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 2 · n 404 · Phase 3 · secondary NCT00432276
  • -0.2 vs 0.3 25 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 0.1 12.5 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.0 12.5 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.2 vs 0.1 12.5 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.2 12.5 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.2 vs 0.3 12.5 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.3 12.5 mg · wk 20 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs -0.4 12.5 mg · wk 16 · n 867 · Phase 3 · secondary NCT00856284
  • -0.1 vs 0.3 12.5 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.5 12.5 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs -0.5 12.5 mg · wk 8 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.6 12.5 mg · wk 4 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.4 12.5 mg · wk 2 · n 867 · Phase 3 · secondary NCT00856284
  • -0.1 vs 0.3 12.5 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -1.4 vs -2.1 25 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.3 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -1.5 vs -2.3 25 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.4 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.1 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -1.5 vs -1.8 25 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.9 vs -0.8 25 mg · wk 2 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8 vs -0.4 25 mg · wk 1 · n 164 · Phase 3 · secondary NCT00395512
  • -1.1 vs -0.3 12.5 mg QD · wk 12 · n 76 · Phase 2/3 · secondary NCT01263483
  • -1.1 vs -0.1 12.5 mg QD · wk 8 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.9 vs -0.0 12.5 mg QD · wk 4 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.9 vs -0.2 12.5 mg QD · wk 2 · n 76 · Phase 2/3 · secondary NCT01263483
  • -2.8 vs -2.1 25 mg + 30 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -3 vs -2.3 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -2.9 vs -2.3 25 mg + 30 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -2.9 vs -2.4 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.9 vs 0.3 25 mg QD · wk 12 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.1 vs -0.1 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.0 vs -0.3 25 mg QD + 0.2 mg TID · wk 12 · n 79 · Phase 2/3 · secondary NCT01263483
  • -2.8 vs -2.1 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.3 25 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.2 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.2 vs -0.1 25 mg QD + 0.2 mg TID · wk 8 · n 79 · Phase 2/3 · secondary NCT01263483
  • -2.3 vs -1.8 25 mg + 30 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -1.3 vs 0.1 25 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.0 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.3 vs -0.0 25 mg QD + 0.2 mg TID · wk 4 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.9 vs -0.8 25 mg + 30 mg · wk 2 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.0 25 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.9 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.0 vs -0.2 25 mg QD + 0.2 mg TID · wk 2 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.5 vs -0.4 25 mg + 30 mg · wk 1 · n 164 · Phase 3 · secondary NCT00395512
  • -2.7 vs -2.1 12.5 mg + 30 mg · wk 26 · n 163 · Phase 3 · secondary NCT00395512
  • -2.6 vs -2.3 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • -2.6 vs -2.3 12.5 mg + 30 mg · wk 16 · n 163 · Phase 3 · secondary NCT00395512
  • -2.7 vs -2.4 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.3 12.5 mg QD · wk 12 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8 vs -0.1 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 111 · Phase 2/3 · secondary NCT01318070
  • -2.7 vs -2.1 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.3 12.5 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.9 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 111 · Phase 2/3 · secondary NCT01318070
  • -2.2 vs -1.8 12.5 mg + 30 mg · wk 4 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.1 12.5 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 111 · Phase 2/3 · secondary NCT01318070
  • -1.7 vs -0.8 12.5 mg + 30 mg · wk 2 · n 163 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.0 12.5 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.7 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 110 · Phase 2/3 · secondary NCT01318070
  • -1.3 vs -0.4 12.5 mg + 30 mg · wk 1 · n 163 · Phase 3 · secondary NCT00395512
  • -1.5 vs 0.5 25 mg QD · wk 12.14 · n 45 · Phase 2 · secondary NCT00755846
  • -1.0 vs 0.3 25 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -1.4 vs 0.3 25 mg QD · wk 6.14 · n 45 · Phase 2 · secondary NCT00755846
  • -1.1 vs 0.5 25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.8 vs 0.1 25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.3 vs 0.5 12.5 mg QD · wk 12.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.8 vs 0.3 12.5 mg QD · wk 12 · n 84 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 12.5 mg QD · wk 8 · n 84 · Phase 2 · secondary NCT01263470
  • -0.6 vs 0.3 12.5 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -1.2 vs 0.5 12.5 mg QD · wk 4 · n 84 · Phase 2 · secondary NCT01263470
  • -0.9 vs 0.1 12.5 mg QD · wk 2 · n 84 · Phase 2 · secondary NCT01263470
  • -1.2 vs 0.5 100 mg QD · wk 12.14 · n 44 · Phase 2 · secondary NCT00755846
  • -1.4 vs 0.3 100 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.9 vs 0.5 50 mg QD · wk 12.14 · n 43 · Phase 2 · secondary NCT00755846
  • -1.3 vs 0.3 50 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -1.3 vs 0.3 50 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 50 mg QD · wk 6.14 · n 43 · Phase 2 · secondary NCT00755846
  • -1.3 vs 0.5 50 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -1.2 vs 0.1 50 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4 vs 0.5 6.25 mg QD · wk 12.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.5 vs 0.3 6.25 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -0.7 vs 0.3 6.25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4 vs 0.3 6.25 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.9 vs 0.5 6.25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.8 vs 0.1 6.25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -1.2 vs -0.7 25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.8 25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.8 25 mg QD · wk 44 · n 63 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 25 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 25 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 25 mg QD · wk 32 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.4 25 mg QD · wk 28 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 25 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.3 25 mg QD · wk 20 · n 88 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.4 25 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.2 25 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 25 mg QD · n 96 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.7 12.5 mg QD · wk 52 · n 59 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.8 12.5 mg QD · wk 48 · n 60 · Phase 2 · secondary NCT01263496
  • -1.0 vs -0.8 12.5 mg QD · wk 44 · n 61 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.8 12.5 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 12.5 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.5 12.5 mg QD · wk 32 · n 81 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.4 12.5 mg QD · wk 28 · n 82 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.5 12.5 mg QD · wk 24 · n 84 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.3 12.5 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.4 12.5 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.2 12.5 mg QD · wk 12 · n 97 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 12.5 mg QD · n 101 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.7 50 mg QD · wk 52 · n 68 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.8 50 mg QD · wk 48 · n 69 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.8 50 mg QD · wk 44 · n 69 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.8 50 mg QD · wk 40 · n 84 · Phase 2 · secondary NCT01263496
  • -1.2 vs -0.5 50 mg QD · wk 36 · n 84 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.5 50 mg QD · wk 32 · n 85 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.4 50 mg QD · wk 28 · n 86 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.5 50 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.3 50 mg QD · wk 20 · n 90 · Phase 2 · secondary NCT01263496
  • -1.0 vs -0.4 50 mg QD · wk 16 · n 97 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.2 50 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -1.5 vs -0.5 50 mg QD · n 97 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.7 6.25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 6.25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 6.25 mg QD · wk 44 · n 65 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.8 6.25 mg QD · wk 40 · n 81 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 6.25 mg QD · wk 32 · n 84 · Phase 2 · secondary NCT01263496
  • -0.5 vs -0.4 6.25 mg QD · wk 28 · n 85 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.3 6.25 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.4 6.25 mg QD · wk 16 · n 88 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.2 6.25 mg QD · wk 12 · n 93 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · n 96 · Phase 2 · secondary NCT01263496
-0.6 vs -0.3−0.2 vs placebo5 mg · wk 24 · n 300NCT00757588
11 other results
  • -0.5 vs -0.3 5 mg · wk 24 · n 139 · Phase 3 · secondary NCT01619059
  • 0.1 vs 0.2 wk 26 · n 80 · Phase 3 · secondary NCT03199053
  • -1.8 vs -0.3 wk 24 · n 158 · Phase 3 · secondary NCT01646320
  • -0.3 vs 0.1 wk 24 · n 121 · Phase 3 · secondary NCT01128153
  • -1.8 vs -0.6 wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • -2.4 vs -1.0 5 mg · wk 26 · n 25 · Phase 3 · secondary NCT03199053
  • -0.6 vs -1.0 2.5 mg · wk 26 · n 23 · Phase 3 · secondary NCT03199053
  • -1.6 vs -1.5 10mg · wk 52 · n 311 · Phase 4 · secondary NCT02471404
  • -0.7 vs -1.3 5 mg · wk 52 · n 344 · Phase 4 · secondary NCT01006603
  • -2.1 vs -1.5 5mg and 10mg · wk 52 · n 312 · Phase 4 · secondary NCT02471404
  • -1.0 vs -1.0 wk 24 · n 238 · Phase 4 · secondary NCT02243176
3-point MACE (% with event)11.3% vs 11.8%−0.5 vs placebon 2701NCT009687087.4% vs 7.4%±0 vs placebon 8280NCT01107886

HbA1c, change

Alogliptin
-0.7% vs -0.1%−0.6 vs placebo25 mg QD · wk 26 · n 126NCT00286429
285 other results
  • -0.6% vs -0.0% 25 mg QD · wk 26 · n 128 · Phase 3 · primary NCT00286455
  • 0.1% vs -0.0% 25 mg · wk 26 · n 54 · Phase 3 · primary NCT02856113
  • -0.5% vs 0.1% 25 mg QD · wk 26 · n 104 · Phase 3 · primary NCT01023581
  • -0.9% vs -0.1% 25 mg · wk 26 · n 123 · Phase 3 · primary NCT00328627
  • -0.8% vs -0.2% 25 mg QD · wk 26 · n 195 · Phase 3 · primary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 26 · n 203 · Phase 3 · primary NCT00286442
  • -0.6% vs -0.1% 12.5 mg QD · wk 26 · n 130 · Phase 3 · primary NCT00286429
  • -0.6% vs -0.0% 12.5 mg QD · wk 26 · n 131 · Phase 3 · primary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 26 · n 104 · Phase 3 · primary NCT01023581
  • -0.6% vs -0.1% 12.5 mg · wk 26 · n 122 · Phase 3 · primary NCT00328627
  • -0.7% vs -0.2% 12.5 mg QD · wk 26 · n 196 · Phase 3 · primary NCT00286494
  • -0.6% vs -0.1% 12.5 mg QD · wk 26 · n 210 · Phase 3 · primary NCT00286442
  • -1.3% vs -0.1% 25 mg + 15 mg · wk 26 · n 127 · Phase 3 · primary NCT00328627
  • -1.4% vs -0.1% 25 mg + 30 mg · wk 26 · n 124 · Phase 3 · primary NCT00328627
  • -1.6% vs -0.1% 25 mg + 45 mg · wk 26 · n 126 · Phase 3 · primary NCT00328627
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 26 · n 102 · Phase 3 · primary NCT01023581
  • -1.6% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 26 · n 111 · Phase 3 · primary NCT01023581
  • -1.3% vs -0.1% 12.5 mg + 15 mg · wk 26 · n 130 · Phase 3 · primary NCT00328627
  • -1.4% vs -0.1% 12.5 mg + 30 mg · wk 26 · n 128 · Phase 3 · primary NCT00328627
  • -1.6% vs -0.1% 12.5 mg + 45 mg · wk 26 · n 127 · Phase 3 · primary NCT00328627
  • -1.0% vs -0.4% wk 16 · n 90 · Phase 3 · primary NCT01289119
  • -0.9% vs -0.4% wk 16 · n 98 · Phase 3 · primary NCT01289119
  • -0.8% vs -0.4% wk 16 · n 60 · Phase 3 · primary NCT01289119
  • -1.0% vs -1.1% 25 mg · wk 26 · n 160 · Phase 3 · primary NCT00395512
  • -0.8% vs -0.7% 25 mg · wk 52 · n 382 · Phase 3 · primary NCT00856284
  • -0.7% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 303 · Phase 3 · primary NCT00432276
  • -0.9% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 303 · Phase 3 · primary NCT00432276
  • -1.0% vs 0.0% 12.5 mg QD · wk 12 · n 76 · Phase 2/3 · primary NCT01263483
  • -1.7% vs -1.1% 25 mg + 30 mg · wk 26 · n 158 · Phase 3 · primary NCT00395512
  • -0.7% vs -0.6% 25 mg · wk 104 · n 382 · Phase 3 · primary NCT00856284
  • -0.8% vs -0.7% 12.5 mg · wk 52 · n 371 · Phase 3 · primary NCT00856284
  • -0.7% vs 0.3% 25 mg QD · wk 12 · n 104 · Phase 2/3 · primary NCT01318083
  • -1.0% vs -0.2% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 113 · Phase 2/3 · primary NCT01318070
  • -0.9% vs 0.0% 25 mg QD + 0.2 mg TID · wk 12 · n 79 · Phase 2/3 · primary NCT01263483
  • -1.6% vs -1.1% 12.5 mg + 30 mg · wk 26 · n 158 · Phase 3 · primary NCT00395512
  • -0.7% vs -0.6% 12.5 mg · wk 104 · n 371 · Phase 3 · primary NCT00856284
  • -0.6% vs 0.3% 12.5 mg QD · wk 12 · n 104 · Phase 2/3 · primary NCT01318083
  • -0.9% vs -0.2% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 111 · Phase 2/3 · primary NCT01318070
  • 0.3% vs 0.8% 25 mg · wk 52 · n 62 · Phase 3 · secondary NCT02856113
  • 0.1% vs 0.5% 25 mg · wk 39 · n 62 · Phase 3 · secondary NCT02856113
  • -0.7% vs -0.2% 25 mg QD · wk 20 · n 126 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 25 mg QD · wk 20 · n 128 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 25 mg QD · wk 20 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.2% 25 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.3% 25 mg QD · wk 20 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 20 · n 203 · Phase 3 · secondary NCT00286442
  • -0.2% vs -0.2% 25 mg · wk 18 · n 62 · Phase 3 · secondary NCT02856113
  • -0.8% vs -0.2% 25 mg QD · wk 16 · n 126 · Phase 3 · secondary NCT00286429
  • -0.7% vs -0.1% 25 mg QD · wk 16 · n 128 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 25 mg QD · wk 16 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.3% 25 mg · wk 16 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.3% 25 mg QD · wk 16 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 16 · n 203 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 25 mg QD · wk 12 · n 126 · Phase 3 · secondary NCT00286429
  • -0.7% vs -0.1% 25 mg QD · wk 12 · n 128 · Phase 3 · secondary NCT00286455
  • -0.4% vs -0.3% 25 mg · wk 12 · n 62 · Phase 3 · secondary NCT02856113
  • -0.5% vs 0.1% 25 mg QD · wk 12 · n 112 · Phase 3 · secondary NCT01023581
  • -0.9% vs -0.3% 25 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.2% 25 mg QD · wk 12 · n 195 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.2% 25 mg QD · wk 12 · n 203 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 25 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 25 mg QD · wk 8 · n 128 · Phase 3 · secondary NCT00286455
  • -0.5% vs 0.1% 25 mg QD · wk 8 · n 112 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 25 mg · wk 8 · n 123 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.2% 25 mg QD · wk 8 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.2% 25 mg QD · wk 8 · n 201 · Phase 3 · secondary NCT00286442
  • -0.6% vs -0.3% 25 mg QD · wk 4 · n 116 · Phase 3 · secondary NCT00286429
  • -0.5% vs -0.1% 25 mg QD · wk 4 · n 120 · Phase 3 · secondary NCT00286455
  • -0.3% vs 0.1% 25 mg QD · wk 4 · n 112 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 25 mg · wk 4 · n 110 · Phase 3 · secondary NCT00328627
  • -0.5% vs -0.1% 25 mg QD · wk 4 · n 176 · Phase 3 · secondary NCT00286494
  • -0.4% vs -0.1% 25 mg QD · wk 4 · n 187 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.2% 12.5 mg QD · wk 20 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 20 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 20 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.2% 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.3% 12.5 mg QD · wk 20 · n 196 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 12.5 mg QD · wk 20 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.2% 12.5 mg QD · wk 16 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 16 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 16 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 16 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.3% 12.5 mg QD · wk 16 · n 196 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.1% 12.5 mg QD · wk 16 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 12.5 mg QD · wk 12 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 12 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 12 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.2% 12.5 mg QD · wk 12 · n 196 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.2% 12.5 mg QD · wk 12 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 12.5 mg QD · wk 8 · n 130 · Phase 3 · secondary NCT00286429
  • -0.5% vs -0.1% 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 8 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg QD · wk 8 · n 196 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.2% 12.5 mg QD · wk 8 · n 210 · Phase 3 · secondary NCT00286442
  • -0.5% vs -0.3% 12.5 mg QD · wk 4 · n 116 · Phase 3 · secondary NCT00286429
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 123 · Phase 3 · secondary NCT00286455
  • -0.4% vs 0.1% 12.5 mg BID · wk 4 · n 110 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 12.5 mg · wk 4 · n 114 · Phase 3 · secondary NCT00328627
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 182 · Phase 3 · secondary NCT00286494
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 188 · Phase 3 · secondary NCT00286442
  • -1.4% vs -0.2% 25 mg + 15 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.2% 25 mg + 30 mg · wk 20 · n 124 · Phase 3 · secondary NCT00328627
  • -1.7% vs -0.2% 25 mg + 45 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 25 mg + 15 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 25 mg + 30 mg · wk 16 · n 124 · Phase 3 · secondary NCT00328627
  • -1.7% vs -0.3% 25 mg + 45 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 25 mg + 15 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 25 mg + 30 mg · wk 12 · n 124 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.3% 25 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.3% 25 mg + 15 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.3% 25 mg + 30 mg · wk 8 · n 124 · Phase 3 · secondary NCT00328627
  • -1.2% vs -0.3% 25 mg + 45 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 15 mg · wk 4 · n 116 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 30 mg · wk 4 · n 118 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 45 mg · wk 4 · n 112 · Phase 3 · secondary NCT00328627
  • -1.3% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 20 · n 106 · Phase 3 · secondary NCT01023581
  • -1.5% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 20 · n 114 · Phase 3 · secondary NCT01023581
  • -1.4% vs -0.2% 12.5 mg + 15 mg · wk 20 · n 130 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.2% 12.5 mg + 30 mg · wk 20 · n 128 · Phase 3 · secondary NCT00328627
  • -1.6% vs -0.2% 12.5 mg + 45 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -1.3% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 16 · n 106 · Phase 3 · secondary NCT01023581
  • -1.5% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 16 · n 114 · Phase 3 · secondary NCT01023581
  • -1.4% vs -0.3% 12.5 mg + 15 mg · wk 16 · n 130 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 12.5 mg + 30 mg · wk 16 · n 128 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.3% 12.5 mg + 45 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 12 · n 106 · Phase 3 · secondary NCT01023581
  • -1.4% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 12 · n 114 · Phase 3 · secondary NCT01023581
  • -1.2% vs -0.3% 12.5 mg + 15 mg · wk 12 · n 130 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 12.5 mg + 30 mg · wk 12 · n 128 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 12.5 mg + 45 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -1.1% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 8 · n 106 · Phase 3 · secondary NCT01023581
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 8 · n 114 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.3% 12.5 mg + 15 mg · wk 8 · n 130 · Phase 3 · secondary NCT00328627
  • -1.1% vs -0.3% 12.5 mg + 30 mg · wk 8 · n 128 · Phase 3 · secondary NCT00328627
  • -1.1% vs -0.3% 12.5 mg + 45 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -0.7% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 4 · n 106 · Phase 3 · secondary NCT01023581
  • -0.8% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 4 · n 114 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 12.5 mg + 15 mg · wk 4 · n 120 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg + 30 mg · wk 4 · n 122 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg + 45 mg · wk 4 · n 117 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.4% wk 12 · n 92 · Phase 3 · secondary NCT01289119
  • -0.9% vs -0.4% wk 12 · n 99 · Phase 3 · secondary NCT01289119
  • -0.8% vs -0.4% wk 12 · n 61 · Phase 3 · secondary NCT01289119
  • -0.9% vs -0.4% wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -0.7% vs -0.4% wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.7% vs -0.4% wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.6% vs -0.2% wk 4 · n 92 · Phase 3 · secondary NCT01289119
  • -0.4% vs -0.2% wk 4 · n 99 · Phase 3 · secondary NCT01289119
  • -0.4% vs -0.2% wk 4 · n 61 · Phase 3 · secondary NCT01289119
  • -1% vs -1.2% 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0% vs -1.2% 25 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0% vs -1.0% 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.7% 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -0.6% vs -0.3% 25 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.7% 25 mg · wk 39 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 25 mg · wk 65 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 34 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.8% 25 mg · wk 26 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 25 mg · wk 78 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 25 mg · wk 20 · n 382 · Phase 3 · secondary NCT00856284
  • -0.9% vs -0.5% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 20 · n 303 · Phase 3 · secondary NCT00432276
  • -0.7% vs -0.0% 12.5 mg QD · wk 8 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.4% vs -0.0% 12.5 mg QD · wk 4 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.2% vs -0.0% 12.5 mg QD · wk 2 · n 76 · Phase 2/3 · secondary NCT01263483
  • -1.7% vs -1.2% 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.8% 25 mg · wk 16 · n 382 · Phase 3 · secondary NCT00856284
  • -0.9% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 16 · n 303 · Phase 3 · secondary NCT00432276
  • -1.7% vs -1.2% 25 mg + 30 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.7% 25 mg · wk 91 · n 382 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.8% 25 mg · wk 12 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 303 · Phase 3 · secondary NCT00432276
  • -1.6% vs -1.0% 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.6% vs -0.7% 25 mg · wk 8 · n 382 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 303 · Phase 3 · secondary NCT00432276
  • -1.2% vs -0.7% 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -0.4% vs -0.4% 25 mg · wk 4 · n 382 · Phase 3 · secondary NCT00856284
  • -0.6% vs 0.2% 25 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8% vs -0.2% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.4% vs -0.1% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.0% 25 mg QD + 0.2 mg TID · wk 8 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.6% vs -0.3% 25 mg + 30 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.7% 12.5 mg · wk 39 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 65 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 26 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 12.5 mg · wk 78 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 20 · n 371 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.8% 12.5 mg · wk 16 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 12.5 mg · wk 91 · n 371 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.8% 12.5 mg · wk 12 · n 371 · Phase 3 · secondary NCT00856284
  • -0.6% vs -0.7% 12.5 mg · wk 8 · n 371 · Phase 3 · secondary NCT00856284
  • -0.4% vs -0.4% 12.5 mg · wk 4 · n 371 · Phase 3 · secondary NCT00856284
  • -0.4% vs 0.1% 25 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.5% vs -0.1% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.4% vs -0.0% 25 mg QD + 0.2 mg TID · wk 4 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.1% vs 0.1% 25 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.2% vs -0.0% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.2% vs -0.0% 25 mg QD + 0.2 mg TID · wk 2 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.5% vs -1.2% 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • -1.4% vs -1.2% 12.5 mg + 30 mg · wk 16 · n 163 · Phase 3 · secondary NCT00395512
  • -1.3% vs -1.0% 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • -1.0% vs -0.7% 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
  • -0.5% vs 0.2% 12.5 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8% vs -0.2% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.5% vs -0.3% 12.5 mg + 30 mg · wk 4 · n 163 · Phase 3 · secondary NCT00395512
  • -0.3% vs 0.1% 12.5 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.5% vs -0.1% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.1% vs 0.1% 12.5 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.2% vs -0.0% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 110 · Phase 2/3 · secondary NCT01318070
  • -0.6% vs -0.0% 25 mg QD · wk 12.14 · n 45 · Phase 2 · primary NCT00755846
  • -0.8% vs 0.1% 25 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.5% vs -0.0% 12.5 mg QD · wk 12.14 · n 42 · Phase 2 · primary NCT00755846
  • -0.7% vs 0.1% 12.5 mg QD · wk 12 · n 84 · Phase 2 · primary NCT01263470
  • -0.5% vs -0.0% 100 mg QD · wk 12.14 · n 44 · Phase 2 · primary NCT00755846
  • -0.4% vs -0.0% 50 mg QD · wk 12.14 · n 43 · Phase 2 · primary NCT00755846
  • -0.8% vs 0.1% 50 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.2% vs -0.0% 6.25 mg QD · wk 12.14 · n 42 · Phase 2 · primary NCT00755846
  • -0.5% vs 0.1% 6.25 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.7% vs 0% 25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4% vs 0.0% 25 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.3% vs -0.0% 25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.6% vs 0% 12.5 mg QD · wk 8 · n 84 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 12.5 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.4% vs -0.0% 12.5 mg QD · wk 4 · n 84 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 12.5 mg QD · wk 2 · n 84 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 100 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.7% vs 0% 50 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 50 mg QD · wk 6.14 · n 43 · Phase 2 · secondary NCT00755846
  • -0.4% vs -0.0% 50 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.1% vs 0% 50 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.5% vs 0% 6.25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.1% vs 0.0% 6.25 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.3% vs -0.0% 6.25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 6.25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.7% vs -0.4% 25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 44 · n 63 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 25 mg QD · wk 32 · n 87 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 28 · n 87 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 20 · n 88 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 25 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.1% 25 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.2% 25 mg QD · n 96 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.4% 12.5 mg QD · wk 52 · n 59 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.4% 12.5 mg QD · wk 48 · n 60 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 44 · n 61 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 12.5 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 12.5 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 32 · n 81 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 28 · n 82 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 24 · n 84 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 12.5 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 12.5 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.1% 12.5 mg QD · wk 12 · n 97 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.2% 12.5 mg QD · n 101 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 50 mg QD · wk 52 · n 68 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 50 mg QD · wk 48 · n 69 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 44 · n 69 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 40 · n 84 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 36 · n 84 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 32 · n 85 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 28 · n 86 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.3% 50 mg QD · wk 20 · n 90 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.3% 50 mg QD · wk 16 · n 91 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.1% 50 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.2% 50 mg QD · n 97 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.4% 6.25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.4% 6.25 mg QD · wk 48 · n 63 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 44 · n 65 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 40 · n 81 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 32 · n 84 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.3% 6.25 mg QD · wk 28 · n 85 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 6.25 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 6.25 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 6.25 mg QD · wk 16 · n 88 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.1% 6.25 mg QD · wk 12 · n 93 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.2% 6.25 mg QD · n 96 · Phase 2 · secondary NCT01263496
Saxagliptin
-0.7% vs -0.3%−0.4 vs placebo5 mg · wk 24 · n 300NCT00757588
19 other results
  • 7.1% vs 7.5% 5 mg · wk 24 · n 275 · Phase 3 · primary NCT00661362
  • -0.5% vs -0.2% 5 mg · wk 24 · n 139 · Phase 3 · primary NCT01619059
  • 0.1% vs 0.5% wk 26 · n 82 · Phase 3 · primary NCT03199053
  • -0.8% vs -0.1% wk 24 · n 158 · Phase 3 · primary NCT01646320
  • -0.7% vs -0.1% wk 24 · n 127 · Phase 3 · primary NCT01128153
  • -0.7% vs 0.6% wk 16 · n 4 · Phase 3 · primary NCT01204775
  • -1% vs 0.9% wk 16 · n 4 · Phase 3 · primary NCT01434186
  • -1.4% vs -1.0% dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 218 · Phase 3 · primary NCT02419612
  • -1.4% vs -1.1% wk 26 · n 224 · Phase 3 · primary NCT02284893
  • -1.7% vs -1.5% wk 24 · n 319 · Phase 3 · primary NCT02551874
  • -1.0% vs -0.7% wk 24 · n 290 · Phase 3 · primary NCT02681094
  • -0.2% vs -0.7% 5 mg · wk 26 · n 25 · Phase 3 · secondary NCT03199053
  • 0.1% vs -0.7% 2.5 mg · wk 26 · n 24 · Phase 3 · secondary NCT03199053
  • -0.8% vs -1.0% 10mg · wk 52 · n 311 · Phase 4 · primary NCT02471404
  • -1.2% vs -1.0% 5mg and 10mg · wk 52 · n 312 · Phase 4 · primary NCT02471404
  • -0.8% vs -0.8% wk 24 · n 238 · Phase 4 · primary NCT02243176
  • -0.8% vs -0.8% wk 24 · n 219 · Phase 4 · primary NCT02243176
  • -0.5% vs -0.4% wk 24 · n 146 · Phase 4 · primary NCT01006590
  • -0.4% vs -0.6% 5 mg · wk 52 · n 353 · Phase 4 · secondary NCT01006603

Body weight, change (kg)

Alogliptin
0.6 vs 0.6±0 vs placebo25 mg QD · wk 26 · n 124NCT00286429
111 other results
  • -0.2 vs 0.2 25 mg QD · wk 26 · n 125 · Phase 3 · secondary NCT00286455
  • -0.7 vs -0.7 25 mg · wk 26 · n 123 · Phase 3 · secondary NCT00328627
  • 1.1 vs 1.0 25 mg QD · wk 26 · n 189 · Phase 3 · secondary NCT00286494
  • -0.7 vs -0.4 25 mg QD · wk 26 · n 198 · Phase 3 · secondary NCT00286442
  • 0.7 vs -0.2 25 mg QD · wk 26 · n 195 · Phase 3 · secondary NCT00286468
  • 0.5 vs 0.7 25 mg QD · wk 20 · n 124 · Phase 3 · secondary NCT00286429
  • -0.2 vs -0.2 25 mg QD · wk 20 · n 125 · Phase 3 · secondary NCT00286455
  • -0.5 vs -0.6 25 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • 0.9 vs 0.9 25 mg QD · wk 20 · n 189 · Phase 3 · secondary NCT00286494
  • -0.6 vs -0.4 25 mg QD · wk 20 · n 198 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.3 25 mg QD · wk 20 · n 195 · Phase 3 · secondary NCT00286468
  • 0.3 vs 0.5 25 mg QD · wk 12 · n 123 · Phase 3 · secondary NCT00286429
  • 0.1 vs -0.3 25 mg QD · wk 12 · n 125 · Phase 3 · secondary NCT00286455
  • -0.6 vs -0.5 25 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • 0.6 vs 0.6 25 mg QD · wk 12 · n 189 · Phase 3 · secondary NCT00286494
  • -0.6 vs -0.6 25 mg QD · wk 12 · n 198 · Phase 3 · secondary NCT00286442
  • 0.4 vs -0.1 25 mg QD · wk 12 · n 194 · Phase 3 · secondary NCT00286468
  • 0.2 vs 0.4 25 mg QD · wk 8 · n 121 · Phase 3 · secondary NCT00286429
  • -0.0 vs -0.4 25 mg QD · wk 8 · n 123 · Phase 3 · secondary NCT00286455
  • -0.5 vs -0.1 25 mg · wk 8 · n 120 · Phase 3 · secondary NCT00328627
  • 0.4 vs 0.4 25 mg QD · wk 8 · n 186 · Phase 3 · secondary NCT00286494
  • -0.5 vs -0.1 25 mg QD · wk 8 · n 193 · Phase 3 · secondary NCT00286442
  • 0.3 vs -0.3 25 mg QD · wk 8 · n 188 · Phase 3 · secondary NCT00286468
  • 0.7 vs 0.6 12.5 mg QD · wk 26 · n 127 · Phase 3 · secondary NCT00286429
  • -0.1 vs 0.2 12.5 mg QD · wk 26 · n 126 · Phase 3 · secondary NCT00286455
  • -0.0 vs -0.7 12.5 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • 1.5 vs 1.0 12.5 mg QD · wk 26 · n 193 · Phase 3 · secondary NCT00286494
  • -0.4 vs -0.4 12.5 mg QD · wk 26 · n 206 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.2 12.5 mg QD · wk 26 · n 197 · Phase 3 · secondary NCT00286468
  • 0.6 vs 0.7 12.5 mg QD · wk 20 · n 127 · Phase 3 · secondary NCT00286429
  • -0.2 vs -0.2 12.5 mg QD · wk 20 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.6 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • 1.1 vs 0.9 12.5 mg QD · wk 20 · n 193 · Phase 3 · secondary NCT00286494
  • -0.4 vs -0.4 12.5 mg QD · wk 20 · n 205 · Phase 3 · secondary NCT00286442
  • 0.8 vs -0.3 12.5 mg QD · wk 20 · n 197 · Phase 3 · secondary NCT00286468
  • 0.4 vs 0.5 12.5 mg QD · wk 12 · n 127 · Phase 3 · secondary NCT00286429
  • -0.4 vs -0.3 12.5 mg QD · wk 12 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.5 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • 0.7 vs 0.6 12.5 mg QD · wk 12 · n 193 · Phase 3 · secondary NCT00286494
  • -0.3 vs -0.6 12.5 mg QD · wk 12 · n 205 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.1 12.5 mg QD · wk 12 · n 197 · Phase 3 · secondary NCT00286468
  • 0.1 vs 0.4 12.5 mg QD · wk 8 · n 125 · Phase 3 · secondary NCT00286429
  • 0.0 vs -0.4 12.5 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.1 12.5 mg · wk 8 · n 119 · Phase 3 · secondary NCT00328627
  • 0.5 vs 0.4 12.5 mg QD · wk 8 · n 190 · Phase 3 · secondary NCT00286494
  • -0.3 vs -0.1 12.5 mg QD · wk 8 · n 198 · Phase 3 · secondary NCT00286442
  • 0.5 vs -0.3 12.5 mg QD · wk 8 · n 194 · Phase 3 · secondary NCT00286468
  • 1.3 vs -0.7 25 mg + 15 mg · wk 26 · n 124 · Phase 3 · secondary NCT00328627
  • 2.1 vs -0.7 25 mg + 30 mg · wk 26 · n 123 · Phase 3 · secondary NCT00328627
  • 2.3 vs -0.7 25 mg + 45 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • 0.8 vs -0.6 25 mg + 15 mg · wk 20 · n 124 · Phase 3 · secondary NCT00328627
  • 1.8 vs -0.6 25 mg + 30 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • 1.8 vs -0.6 25 mg + 45 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • 0.4 vs -0.5 25 mg + 15 mg · wk 12 · n 124 · Phase 3 · secondary NCT00328627
  • 1.0 vs -0.5 25 mg + 30 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • 1.1 vs -0.5 25 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • 0.2 vs -0.1 25 mg + 15 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • 0.7 vs -0.1 25 mg + 30 mg · wk 8 · n 121 · Phase 3 · secondary NCT00328627
  • 0.9 vs -0.1 25 mg + 45 mg · wk 8 · n 124 · Phase 3 · secondary NCT00328627
  • 1.3 vs -0.7 12.5 mg + 15 mg · wk 26 · n 127 · Phase 3 · secondary NCT00328627
  • 1.9 vs -0.7 12.5 mg + 30 mg · wk 26 · n 125 · Phase 3 · secondary NCT00328627
  • 2.3 vs -0.7 12.5 mg + 45 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • 1.0 vs -0.6 12.5 mg + 15 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • 1.4 vs -0.6 12.5 mg + 30 mg · wk 20 · n 125 · Phase 3 · secondary NCT00328627
  • 1.9 vs -0.6 12.5 mg + 45 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • 0.2 vs -0.5 12.5 mg + 15 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • 0.6 vs -0.5 12.5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT00328627
  • 0.9 vs -0.5 12.5 mg + 45 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • 0.1 vs -0.1 12.5 mg + 15 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • 0.5 vs -0.1 12.5 mg + 30 mg · wk 8 · n 125 · Phase 3 · secondary NCT00328627
  • 0.4 vs -0.1 12.5 mg + 45 mg · wk 8 · n 121 · Phase 3 · secondary NCT00328627
  • -0.9 vs -1.6 wk 16 · n 92 · Phase 3 · secondary NCT01289119
  • -0.8 vs -1.6 wk 16 · n 99 · Phase 3 · secondary NCT01289119
  • -0.1 vs -1.6 wk 16 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7 vs -1.0 wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -0.4 vs -1.0 wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.1 vs -1.0 wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.9 vs 0.9 25 mg · wk 52 · n 868 · Phase 3 · secondary NCT00856284
  • 1.1 vs 1.6 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 404 · Phase 3 · secondary NCT00432276
  • 1.1 vs 1.5 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs 1.0 25 mg · wk 39 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 65 · n 868 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 25 mg · wk 26 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 78 · n 868 · Phase 3 · secondary NCT00856284
  • 0.7 vs 1.0 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs 0.9 25 mg · wk 91 · n 868 · Phase 3 · secondary NCT00856284
  • -0.5 vs 0.7 25 mg · wk 12 · n 868 · Phase 3 · secondary NCT00856284
  • 0.3 vs 0.6 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 404 · Phase 3 · secondary NCT00432276
  • 0.3 vs 0.5 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 404 · Phase 3 · secondary NCT00432276
  • 0.2 vs 0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs 0.9 25 mg · wk 104 · n 868 · Phase 3 · secondary NCT00856284
  • -0.6 vs 0.9 12.5 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs 1.0 12.5 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.8 vs 0.9 12.5 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs 0.7 12.5 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 2.2 25 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -0.5 vs 1.6 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8 vs 1.0 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.3 vs 0.6 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • 3.1 vs 2.2 25 mg + 30 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • 2.4 vs 1.6 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • 1.4 vs 1.0 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • 0.8 vs 0.6 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • 2.5 vs 2.2 12.5 mg + 30 mg · wk 26 · n 163 · Phase 3 · secondary NCT00395512
  • 1.9 vs 1.6 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • 1.2 vs 1.0 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • 0.7 vs 0.6 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
Saxagliptin
-1.9 vs -0.4−1.5 vs placebowk 24 · n 158NCT01646320
7 other results
  • -3.1 vs 0.9 dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 224 · Phase 3 · secondary NCT02419612
  • -1.9 vs -0.5 wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • -1.5 vs 2.1 wk 24 · n 319 · Phase 3 · secondary NCT02551874
  • -2.0 vs -0.4 wk 24 · n 290 · Phase 3 · secondary NCT02681094
  • -3.5 vs 1.8 10mg · wk 52 · n 311 · Phase 4 · secondary NCT02471404
  • -3.1 vs 1.8 5mg and 10mg · wk 52 · n 312 · Phase 4 · secondary NCT02471404
  • -1.4 vs -2.0 wk 24 · n 238 · Phase 4 · secondary NCT02243176

HbA1c below 7%

Alogliptin
63.3% vs 30%+33.3 vs placebowk 16 · n 90NCT01289119
2 other results
  • 55.1% vs 30% wk 16 · n 98 · Phase 3 · secondary NCT01289119
  • 61.7% vs 30% wk 16 · n 60 · Phase 3 · secondary NCT01289119
Saxagliptin
44.4% vs 16.6%+27.8 vs placebo10 mg · wk 24 · n 180NCT00121667
15 other results
  • 41.1% vs 23.9% 10 mg · wk 24 · n 95 · Phase 3 · secondary NCT00121641
  • 43.5% vs 16.6% 5 mg · wk 24 · n 186 · Phase 3 · secondary NCT00121667
  • 37.9% vs 23.9% 5 mg · wk 24 · n 103 · Phase 3 · secondary NCT00121641
  • 22.1% vs 13.3% 5 mg · wk 24 · n 104 · Phase 3 · secondary NCT00918879
  • 45.8% vs 28.8% 5 mg · wk 24 · n 277 · Phase 3 · secondary NCT00698932
  • 37.1% vs 16.6% 2.5 mg · wk 24 · n 186 · Phase 3 · secondary NCT00121667
  • 35% vs 23.9% 2.5 mg · wk 24 · n 100 · Phase 3 · secondary NCT00121641
  • 37.5% vs 24.2% 2.5 mg · wk 12 · n 73 · Phase 3 · secondary NCT00885378
  • 21.3% vs 10% wk 26 · n 61 · Phase 3 · secondary NCT03199053
  • 36.7% vs 13.3% wk 24 · n 158 · Phase 3 · secondary NCT01646320
  • 21.4% vs 11.7% dapagliflozin 10 mg, saxagliptin 5 mg · wk 156 · n 227 · Phase 3 · secondary NCT02419612
  • 44.3% vs 34.3% dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 227 · Phase 3 · secondary NCT02419612
  • 37.3% vs 25.1% wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • 37.2% vs 26.1% wk 18 · n 137 · Phase 3 · secondary NCT00960076
  • 38.3% vs 41.5% wk 24 · n 230 · Phase 4 · secondary NCT02243176

Fasting plasma glucose, change

Alogliptin
-0.7 vs 0.3−1 vs placebo25 mg QD · wk 26 · n 128NCT00286429
351 other results
  • -0.9 vs 0.6 25 mg QD · wk 26 · n 131 · Phase 3 · secondary NCT00286455
  • -0.3 vs 0.7 25 mg QD · wk 26 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0 vs 0.4 25 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.3 25 mg QD · wk 26 · n 197 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0 25 mg QD · wk 26 · n 204 · Phase 3 · secondary NCT00286442
  • -0.5 vs 0.1 25 mg QD · wk 26 · n 198 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.5 25 mg QD · wk 20 · n 128 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.4 25 mg QD · wk 20 · n 129 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.5 25 mg QD · wk 20 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.4 25 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.4 25 mg QD · wk 20 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs -0.0 25 mg QD · wk 20 · n 204 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.0 25 mg QD · wk 20 · n 198 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 25 mg QD · wk 16 · n 128 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.3 25 mg QD · wk 16 · n 129 · Phase 3 · secondary NCT00286455
  • -0.4 vs 0.6 25 mg QD · wk 16 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.1 25 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.5 25 mg QD · wk 16 · n 197 · Phase 3 · secondary NCT00286494
  • -0.8 vs 0.1 25 mg QD · wk 16 · n 204 · Phase 3 · secondary NCT00286442
  • -0.7 vs -0.4 25 mg QD · wk 16 · n 198 · Phase 3 · secondary NCT00286468
  • -0.2 vs -0.1 25 mg QD · wk 12 · n 128 · Phase 3 · secondary NCT00286429
  • -1.1 vs 0.1 25 mg QD · wk 12 · n 129 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.6 25 mg QD · wk 12 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.2 25 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -1.4 vs -0.6 25 mg QD · wk 12 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 25 mg QD · wk 12 · n 204 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 25 mg QD · wk 12 · n 198 · Phase 3 · secondary NCT00286468
  • -0.8 vs 0.3 25 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286429
  • -1.1 vs 0.1 25 mg QD · wk 8 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.4 25 mg QD · wk 8 · n 112 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 25 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -1.5 vs -0.3 25 mg QD · wk 8 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 25 mg QD · wk 8 · n 204 · Phase 3 · secondary NCT00286442
  • -1.0 vs -0.2 25 mg QD · wk 8 · n 198 · Phase 3 · secondary NCT00286468
  • -0.7 vs 0.3 25 mg QD · wk 4 · n 120 · Phase 3 · secondary NCT00286429
  • -1.2 vs 0.2 25 mg QD · wk 4 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.4 25 mg QD · wk 4 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.2 25 mg · wk 4 · n 125 · Phase 3 · secondary NCT00328627
  • -1.4 vs -0.2 25 mg QD · wk 4 · n 197 · Phase 3 · secondary NCT00286494
  • -1 vs -0.0 25 mg QD · wk 4 · n 204 · Phase 3 · secondary NCT00286442
  • -1.2 vs -0.2 25 mg QD · wk 4 · n 197 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.1 25 mg QD · wk 2 · n 119 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.2 25 mg QD · wk 2 · n 126 · Phase 3 · secondary NCT00286455
  • -0.4 vs 0.3 25 mg QD · wk 2 · n 112 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 25 mg · wk 2 · n 125 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.1 25 mg QD · wk 2 · n 193 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 25 mg QD · wk 2 · n 199 · Phase 3 · secondary NCT00286442
  • -1.2 vs -0.1 25 mg QD · wk 2 · n 194 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.3 25 mg QD · wk 1 · n 111 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.3 25 mg QD · wk 1 · n 121 · Phase 3 · secondary NCT00286455
  • -0.2 vs 0.3 25 mg QD · wk 1 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0 vs 0.1 25 mg · wk 1 · n 117 · Phase 3 · secondary NCT00328627
  • -1.0 vs -0.1 25 mg QD · wk 1 · n 171 · Phase 3 · secondary NCT00286494
  • -0.7 vs -0.0 25 mg QD · wk 1 · n 186 · Phase 3 · secondary NCT00286442
  • -1.1 vs 0.0 25 mg QD · wk 1 · n 185 · Phase 3 · secondary NCT00286468
  • 0.1 vs 0.3 12.5 mg QD · wk 26 · n 131 · Phase 3 · secondary NCT00286429
  • -0.6 vs 0.6 12.5 mg QD · wk 26 · n 132 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.7 12.5 mg BID · wk 26 · n 110 · Phase 3 · secondary NCT01023581
  • -0.7 vs 0.4 12.5 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.3 12.5 mg QD · wk 26 · n 196 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0 12.5 mg QD · wk 26 · n 211 · Phase 3 · secondary NCT00286442
  • -0.3 vs 0.1 12.5 mg QD · wk 26 · n 201 · Phase 3 · secondary NCT00286468
  • -0.2 vs 0.5 12.5 mg QD · wk 20 · n 131 · Phase 3 · secondary NCT00286429
  • -0.7 vs 0.4 12.5 mg QD · wk 20 · n 132 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.5 12.5 mg BID · wk 20 · n 110 · Phase 3 · secondary NCT01023581
  • -0.5 vs 0.4 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.4 12.5 mg QD · wk 20 · n 196 · Phase 3 · secondary NCT00286494
  • -1 vs -0.0 12.5 mg QD · wk 20 · n 211 · Phase 3 · secondary NCT00286442
  • -0.5 vs -0.0 12.5 mg QD · wk 20 · n 201 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 16 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.3 12.5 mg QD · wk 16 · n 132 · Phase 3 · secondary NCT00286455
  • -0.8 vs 0.6 12.5 mg BID · wk 16 · n 110 · Phase 3 · secondary NCT01023581
  • -0.9 vs 0.1 12.5 mg · wk 16 · n 122 · Phase 3 · secondary NCT00328627
  • -1.0 vs -0.5 12.5 mg QD · wk 16 · n 196 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0.1 12.5 mg QD · wk 16 · n 211 · Phase 3 · secondary NCT00286442
  • -0.5 vs -0.4 12.5 mg QD · wk 16 · n 201 · Phase 3 · secondary NCT00286468
  • -0.3 vs -0.1 12.5 mg QD · wk 12 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.1 12.5 mg QD · wk 12 · n 132 · Phase 3 · secondary NCT00286455
  • -0.8 vs 0.6 12.5 mg BID · wk 12 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.2 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.6 12.5 mg QD · wk 12 · n 196 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 12.5 mg QD · wk 12 · n 211 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 12.5 mg QD · wk 12 · n 201 · Phase 3 · secondary NCT00286468
  • -0.8 vs 0.3 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.1 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.4 12.5 mg BID · wk 8 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 12.5 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.3 12.5 mg QD · wk 8 · n 196 · Phase 3 · secondary NCT00286494
  • -1.1 vs 0.0 12.5 mg QD · wk 8 · n 211 · Phase 3 · secondary NCT00286442
  • -1.1 vs -0.2 12.5 mg QD · wk 8 · n 200 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 4 · n 128 · Phase 3 · secondary NCT00286429
  • -0.9 vs 0.2 12.5 mg QD · wk 4 · n 131 · Phase 3 · secondary NCT00286455
  • -0.9 vs 0.4 12.5 mg BID · wk 4 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.2 12.5 mg · wk 4 · n 122 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.2 12.5 mg QD · wk 4 · n 194 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 12.5 mg QD · wk 4 · n 211 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 12.5 mg QD · wk 4 · n 198 · Phase 3 · secondary NCT00286468
  • -0.2 vs 0.1 12.5 mg QD · wk 2 · n 127 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.2 12.5 mg QD · wk 2 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.3 12.5 mg BID · wk 2 · n 110 · Phase 3 · secondary NCT01023581
  • -1.2 vs 0.3 12.5 mg · wk 2 · n 120 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.1 12.5 mg QD · wk 2 · n 189 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 12.5 mg QD · wk 2 · n 208 · Phase 3 · secondary NCT00286442
  • -0.9 vs -0.1 12.5 mg QD · wk 2 · n 197 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 1 · n 121 · Phase 3 · secondary NCT00286429
  • -0.5 vs 0.3 12.5 mg QD · wk 1 · n 120 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.3 12.5 mg BID · wk 1 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8 vs 0.1 12.5 mg · wk 1 · n 114 · Phase 3 · secondary NCT00328627
  • -0.8 vs -0.1 12.5 mg QD · wk 1 · n 176 · Phase 3 · secondary NCT00286494
  • -0.8 vs -0.0 12.5 mg QD · wk 1 · n 193 · Phase 3 · secondary NCT00286442
  • -0.7 vs 0.0 12.5 mg QD · wk 1 · n 189 · Phase 3 · secondary NCT00286468
  • -2.1 vs 0.4 25 mg + 15 mg · wk 26 · n 130 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 25 mg + 30 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 25 mg + 45 mg · wk 26 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.4 25 mg + 15 mg · wk 20 · n 130 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.4 25 mg + 30 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 25 mg + 45 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.1 25 mg + 15 mg · wk 16 · n 130 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.1 25 mg + 30 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -3.0 vs 0.1 25 mg + 45 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.2 25 mg + 15 mg · wk 12 · n 130 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.2 25 mg + 30 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.2 25 mg + 45 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.3 25 mg + 15 mg · wk 8 · n 130 · Phase 3 · secondary NCT00328627
  • -2.5 vs 0.3 25 mg + 30 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.3 25 mg + 45 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 25 mg + 15 mg · wk 4 · n 130 · Phase 3 · secondary NCT00328627
  • -2 vs 0.2 25 mg + 30 mg · wk 4 · n 126 · Phase 3 · secondary NCT00328627
  • -2.6 vs 0.2 25 mg + 45 mg · wk 4 · n 127 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 25 mg + 15 mg · wk 2 · n 129 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 25 mg + 30 mg · wk 2 · n 126 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 25 mg + 45 mg · wk 2 · n 126 · Phase 3 · secondary NCT00328627
  • -1.2 vs 0.1 25 mg + 15 mg · wk 1 · n 123 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 25 mg + 30 mg · wk 1 · n 118 · Phase 3 · secondary NCT00328627
  • -1.4 vs 0.1 25 mg + 45 mg · wk 1 · n 113 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.7 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 26 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.7 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 26 · n 114 · Phase 3 · secondary NCT01023581
  • -2.3 vs 0.4 12.5 mg + 15 mg · wk 26 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 12.5 mg + 30 mg · wk 26 · n 129 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 12.5 mg + 45 mg · wk 26 · n 128 · Phase 3 · secondary NCT00328627
  • -1.9 vs 0.5 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 20 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.5 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 20 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.4 12.5 mg + 15 mg · wk 20 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 12.5 mg + 30 mg · wk 20 · n 129 · Phase 3 · secondary NCT00328627
  • -2.6 vs 0.4 12.5 mg + 45 mg · wk 20 · n 128 · Phase 3 · secondary NCT00328627
  • -2.0 vs 0.6 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 16 · n 106 · Phase 3 · secondary NCT01023581
  • -2.6 vs 0.6 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 16 · n 114 · Phase 3 · secondary NCT01023581
  • -2.3 vs 0.1 12.5 mg + 15 mg · wk 16 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.1 12.5 mg + 30 mg · wk 16 · n 129 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.1 12.5 mg + 45 mg · wk 16 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.6 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 12 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.6 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 12 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.2 12.5 mg + 15 mg · wk 12 · n 129 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.2 12.5 mg + 30 mg · wk 12 · n 129 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.2 12.5 mg + 45 mg · wk 12 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.4 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 8 · n 106 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.4 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 8 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.3 12.5 mg + 15 mg · wk 8 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.3 12.5 mg + 30 mg · wk 8 · n 129 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.3 12.5 mg + 45 mg · wk 8 · n 128 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.4 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 4 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.4 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 4 · n 114 · Phase 3 · secondary NCT01023581
  • -2.0 vs 0.2 12.5 mg + 15 mg · wk 4 · n 129 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 12.5 mg + 30 mg · wk 4 · n 129 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 12.5 mg + 45 mg · wk 4 · n 128 · Phase 3 · secondary NCT00328627
  • -1.9 vs 0.3 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 2 · n 106 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.3 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 2 · n 114 · Phase 3 · secondary NCT01023581
  • -1.7 vs 0.3 12.5 mg + 15 mg · wk 2 · n 127 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 12.5 mg + 30 mg · wk 2 · n 128 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 12.5 mg + 45 mg · wk 2 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 1 · n 106 · Phase 3 · secondary NCT01023581
  • -2.0 vs 0.3 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 1 · n 114 · Phase 3 · secondary NCT01023581
  • -1.2 vs 0.1 12.5 mg + 15 mg · wk 1 · n 121 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 12.5 mg + 30 mg · wk 1 · n 119 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 12.5 mg + 45 mg · wk 1 · n 115 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.3 wk 16 · n 92 · Phase 3 · secondary NCT01289119
  • -1.2 vs -0.3 wk 16 · n 99 · Phase 3 · secondary NCT01289119
  • -0.9 vs 0.7 25 mg QD · wk 16 · n 25 · Phase 3 · secondary NCT00655863
  • -0.9 vs 0.3 25 mg QD · wk 8 · n 25 · Phase 3 · secondary NCT00655863
  • -1.1 vs -0.2 25 mg QD · wk 4 · n 25 · Phase 3 · secondary NCT00655863
  • -2.1 vs 0.7 25 mg QD + 30 mg QD · wk 16 · n 22 · Phase 3 · secondary NCT00655863
  • -2.1 vs 0.3 25 mg QD + 30 mg QD · wk 8 · n 22 · Phase 3 · secondary NCT00655863
  • -2.2 vs -0.2 25 mg QD + 30 mg QD · wk 4 · n 22 · Phase 3 · secondary NCT00655863
  • -1.1 vs -0.3 wk 16 · n 61 · Phase 3 · secondary NCT01289119
  • -1.1 vs -0.4 wk 12 · n 92 · Phase 3 · secondary NCT01289119
  • -1.3 vs -0.4 wk 12 · n 99 · Phase 3 · secondary NCT01289119
  • -1.2 vs -0.4 wk 12 · n 61 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -1.3 vs -0.3 wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.9 vs -0.3 wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7 vs -0.3 wk 4 · n 92 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 4 · n 99 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 4 · n 61 · Phase 3 · secondary NCT01289119
  • -0.4 vs 0.1 25 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.8 vs -0.2 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 404 · Phase 3 · secondary NCT00432276
  • -0.5 vs -0.0 25 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 0.1 25 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.8 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 34 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.2 25 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 0.3 25 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.3 25 mg · wk 20 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 20 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.4 25 mg · wk 16 · n 867 · Phase 3 · secondary NCT00856284
  • -1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 16 · n 404 · Phase 3 · secondary NCT00432276
  • -0.2 vs 0.3 25 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.5 25 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -1.1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.5 25 mg · wk 8 · n 867 · Phase 3 · secondary NCT00856284
  • -1.1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.6 25 mg · wk 4 · n 867 · Phase 3 · secondary NCT00856284
  • -1.0 vs -0.1 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.4 25 mg · wk 2 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.0 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 2 · n 404 · Phase 3 · secondary NCT00432276
  • -0.2 vs 0.3 25 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 0.1 12.5 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.0 12.5 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.2 vs 0.1 12.5 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.2 12.5 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.2 vs 0.3 12.5 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.3 12.5 mg · wk 20 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs -0.4 12.5 mg · wk 16 · n 867 · Phase 3 · secondary NCT00856284
  • -0.1 vs 0.3 12.5 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.5 12.5 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs -0.5 12.5 mg · wk 8 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.6 12.5 mg · wk 4 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.4 12.5 mg · wk 2 · n 867 · Phase 3 · secondary NCT00856284
  • -0.1 vs 0.3 12.5 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -1.4 vs -2.1 25 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.3 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -1.5 vs -2.3 25 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.4 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.1 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -1.5 vs -1.8 25 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.9 vs -0.8 25 mg · wk 2 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8 vs -0.4 25 mg · wk 1 · n 164 · Phase 3 · secondary NCT00395512
  • -1.1 vs -0.3 12.5 mg QD · wk 12 · n 76 · Phase 2/3 · secondary NCT01263483
  • -1.1 vs -0.1 12.5 mg QD · wk 8 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.9 vs -0.0 12.5 mg QD · wk 4 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.9 vs -0.2 12.5 mg QD · wk 2 · n 76 · Phase 2/3 · secondary NCT01263483
  • -2.8 vs -2.1 25 mg + 30 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -3 vs -2.3 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -2.9 vs -2.3 25 mg + 30 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -2.9 vs -2.4 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.9 vs 0.3 25 mg QD · wk 12 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.1 vs -0.1 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.0 vs -0.3 25 mg QD + 0.2 mg TID · wk 12 · n 79 · Phase 2/3 · secondary NCT01263483
  • -2.8 vs -2.1 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.3 25 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.2 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.2 vs -0.1 25 mg QD + 0.2 mg TID · wk 8 · n 79 · Phase 2/3 · secondary NCT01263483
  • -2.3 vs -1.8 25 mg + 30 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -1.3 vs 0.1 25 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.0 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.3 vs -0.0 25 mg QD + 0.2 mg TID · wk 4 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.9 vs -0.8 25 mg + 30 mg · wk 2 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.0 25 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.9 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.0 vs -0.2 25 mg QD + 0.2 mg TID · wk 2 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.5 vs -0.4 25 mg + 30 mg · wk 1 · n 164 · Phase 3 · secondary NCT00395512
  • -2.7 vs -2.1 12.5 mg + 30 mg · wk 26 · n 163 · Phase 3 · secondary NCT00395512
  • -2.6 vs -2.3 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • -2.6 vs -2.3 12.5 mg + 30 mg · wk 16 · n 163 · Phase 3 · secondary NCT00395512
  • -2.7 vs -2.4 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.3 12.5 mg QD · wk 12 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8 vs -0.1 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 111 · Phase 2/3 · secondary NCT01318070
  • -2.7 vs -2.1 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.3 12.5 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.9 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 111 · Phase 2/3 · secondary NCT01318070
  • -2.2 vs -1.8 12.5 mg + 30 mg · wk 4 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.1 12.5 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 111 · Phase 2/3 · secondary NCT01318070
  • -1.7 vs -0.8 12.5 mg + 30 mg · wk 2 · n 163 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.0 12.5 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.7 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 110 · Phase 2/3 · secondary NCT01318070
  • -1.3 vs -0.4 12.5 mg + 30 mg · wk 1 · n 163 · Phase 3 · secondary NCT00395512
  • -1.5 vs 0.5 25 mg QD · wk 12.14 · n 45 · Phase 2 · secondary NCT00755846
  • -1.0 vs 0.3 25 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -1.4 vs 0.3 25 mg QD · wk 6.14 · n 45 · Phase 2 · secondary NCT00755846
  • -1.1 vs 0.5 25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.8 vs 0.1 25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.3 vs 0.5 12.5 mg QD · wk 12.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.8 vs 0.3 12.5 mg QD · wk 12 · n 84 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 12.5 mg QD · wk 8 · n 84 · Phase 2 · secondary NCT01263470
  • -0.6 vs 0.3 12.5 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -1.2 vs 0.5 12.5 mg QD · wk 4 · n 84 · Phase 2 · secondary NCT01263470
  • -0.9 vs 0.1 12.5 mg QD · wk 2 · n 84 · Phase 2 · secondary NCT01263470
  • -1.2 vs 0.5 100 mg QD · wk 12.14 · n 44 · Phase 2 · secondary NCT00755846
  • -1.4 vs 0.3 100 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.9 vs 0.5 50 mg QD · wk 12.14 · n 43 · Phase 2 · secondary NCT00755846
  • -1.3 vs 0.3 50 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -1.3 vs 0.3 50 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 50 mg QD · wk 6.14 · n 43 · Phase 2 · secondary NCT00755846
  • -1.3 vs 0.5 50 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -1.2 vs 0.1 50 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4 vs 0.5 6.25 mg QD · wk 12.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.5 vs 0.3 6.25 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -0.7 vs 0.3 6.25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4 vs 0.3 6.25 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.9 vs 0.5 6.25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.8 vs 0.1 6.25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -1.2 vs -0.7 25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.8 25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.8 25 mg QD · wk 44 · n 63 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 25 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 25 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 25 mg QD · wk 32 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.4 25 mg QD · wk 28 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 25 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.3 25 mg QD · wk 20 · n 88 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.4 25 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.2 25 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 25 mg QD · n 96 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.7 12.5 mg QD · wk 52 · n 59 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.8 12.5 mg QD · wk 48 · n 60 · Phase 2 · secondary NCT01263496
  • -1.0 vs -0.8 12.5 mg QD · wk 44 · n 61 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.8 12.5 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 12.5 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.5 12.5 mg QD · wk 32 · n 81 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.4 12.5 mg QD · wk 28 · n 82 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.5 12.5 mg QD · wk 24 · n 84 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.3 12.5 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.4 12.5 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.2 12.5 mg QD · wk 12 · n 97 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 12.5 mg QD · n 101 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.7 50 mg QD · wk 52 · n 68 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.8 50 mg QD · wk 48 · n 69 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.8 50 mg QD · wk 44 · n 69 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.8 50 mg QD · wk 40 · n 84 · Phase 2 · secondary NCT01263496
  • -1.2 vs -0.5 50 mg QD · wk 36 · n 84 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.5 50 mg QD · wk 32 · n 85 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.4 50 mg QD · wk 28 · n 86 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.5 50 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.3 50 mg QD · wk 20 · n 90 · Phase 2 · secondary NCT01263496
  • -1.0 vs -0.4 50 mg QD · wk 16 · n 97 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.2 50 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -1.5 vs -0.5 50 mg QD · n 97 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.7 6.25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 6.25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 6.25 mg QD · wk 44 · n 65 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.8 6.25 mg QD · wk 40 · n 81 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 6.25 mg QD · wk 32 · n 84 · Phase 2 · secondary NCT01263496
  • -0.5 vs -0.4 6.25 mg QD · wk 28 · n 85 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.3 6.25 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.4 6.25 mg QD · wk 16 · n 88 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.2 6.25 mg QD · wk 12 · n 93 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · n 96 · Phase 2 · secondary NCT01263496
Saxagliptin
-0.6 vs -0.3−0.2 vs placebo5 mg · wk 24 · n 300NCT00757588
11 other results
  • -0.5 vs -0.3 5 mg · wk 24 · n 139 · Phase 3 · secondary NCT01619059
  • 0.1 vs 0.2 wk 26 · n 80 · Phase 3 · secondary NCT03199053
  • -1.8 vs -0.3 wk 24 · n 158 · Phase 3 · secondary NCT01646320
  • -0.3 vs 0.1 wk 24 · n 121 · Phase 3 · secondary NCT01128153
  • -1.8 vs -0.6 wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • -2.4 vs -1.0 5 mg · wk 26 · n 25 · Phase 3 · secondary NCT03199053
  • -0.6 vs -1.0 2.5 mg · wk 26 · n 23 · Phase 3 · secondary NCT03199053
  • -1.6 vs -1.5 10mg · wk 52 · n 311 · Phase 4 · secondary NCT02471404
  • -0.7 vs -1.3 5 mg · wk 52 · n 344 · Phase 4 · secondary NCT01006603
  • -2.1 vs -1.5 5mg and 10mg · wk 52 · n 312 · Phase 4 · secondary NCT02471404
  • -1.0 vs -1.0 wk 24 · n 238 · Phase 4 · secondary NCT02243176

3-point MACE (% with event)

Alogliptin
11.3% vs 11.8%−0.5 vs placebon 2701NCT00968708
Saxagliptin
7.4% vs 7.4%±0 vs placebon 8280NCT01107886
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
9 other shared endpoints and safety

Coverage. Alogliptin: 13 of 13 rows · Saxagliptin: 13 of 13 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlogliptin
Rows use multiple source trials
Saxagliptin
Rows use multiple source trials
Fasting Plasma Glucose
absolute change · mmol/L
No placebo or comparator arm
-0.87 mmol/L @ 24wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TIDa,b,c,d
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -15.6 mg/dL as posted
show 3 more doses
-1.29 mmol/L*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -23.3 mg/dL as posted
-0.77 mmol/L @ 24wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -13.8 mg/dL as posted
-0.97 mmol/L*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -17.5 mg/dL as posted
-0.55 mmol/L @ 24wkb,c,d
NCT01608724 · Phase 4 · registry result, not featured evidence
1 other source trial
-0.62 mmol/L @ 24wk*
NCT02104804 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -11.23 mg/dL as posted
Glycemic Rescue
responder rate · % of participants
12.8% (n=125) vs 32.8% (n=125) placebo25 mga,c,e
NCT00328627 · Phase 3 · registry result, not featured evidence
show 7 more doses
14.5% (n=124) vs 32.8% (n=125) placebo12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
3.9% (n=129) vs 32.8% (n=125) placebo25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
4.9% (n=123) vs 32.8% (n=125) placebo25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.6% (n=125) vs 32.8% (n=125) placebo25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
4.7% (n=129) vs 32.8% (n=125) placebo12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
4.8% (n=126) vs 32.8% (n=125) placebo12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
2.4% (n=127) vs 32.8% (n=125) placebo12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
37% (n=227) vs 55.6% (n=216) Glimepiride @ 156wkdapagliflozin 10 mg, saxagliptin 5 mgc,e
NCT02419612 · Phase 3 · registry result, not featured evidence
HbA1c
absolute change · percentage points
No placebo or comparator arm
-0.7% (n=145) @ 24wk25 mg QD and 1-6 mg QD or BIDa,f,c
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
show 3 more doses
-0.78% (n=134) @ 24wk25 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
-0.59% (n=137) @ 24wk12.5 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
-0.68% (n=135) @ 24wk12.5 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
-0.64% (n=229) @ 24wkf,c
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
HbA1c 7.0 or Less
event count · % of participants
7.8% (n=129) vs 0.8% (n=129) placebo @ 26wk*25 mg QDa,c,d,g
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 10 participants as posted
show 1 more dose
8.4% (n=131) vs 0.8% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 11 participants as posted
30.7% (n=127) vs 9.4% (n=127) placebo @ 24wk*c,d,g
NCT01128153 · Phase 3 · registry result, not featured evidence · converted to % from 39 Participants as posted
HbA1c Less Than 7%
event count · % of participants
44.4% (n=207) vs 18.3% (n=104) placebo @ 26wk*25 mg QDa,c,d,g
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 92 participants as posted
show 1 more dose
51.6% (n=213) vs 18.3% (n=104) placebo @ 26wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 110 participants as posted
42.8% (n=290) vs 21.8% (n=289) Dapagliflozin + Metformin @ 24wk*c,d,g
NCT02681094 · Phase 3 · registry result, not featured evidence · add on · converted to % from 124 Participants as posted
HbA1c Less Than or Equal to 6.5
responder rate · % of participants
24.1% (n=878) vs 19% (n=869) Glipizide @ 104wk25 mga,c,h
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
23.5% (n=873) vs 19% (n=869) Glipizide @ 104wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
24.6% (n=74) vs 10.7% (n=84) placebo @ 12wk2.5 mgc,h
NCT00885378 · Phase 3 · registry result, not featured evidence · combination
PPG 2h Change mg/dL
absolute change · mmol/L
3.08 vs 3.14 Voglibose mmol/L @ 24wk*25 mg QDa,i,c,d
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 55.5 mg/dL as posted
show 7 more doses
3.35 vs 2.92 Voglibose mmol/L*25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 60.4 mg/dL as posted
3.08 vs 3.14 Voglibose mmol/L @ 24wk*12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 55.5 mg/dL as posted
3.54 vs 2.92 Voglibose mmol/L*12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 63.8 mg/dL as posted
3.1 vs 3.14 Voglibose mmol/L @ 24wk*50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 55.9 mg/dL as posted
2.92 vs 2.92 Voglibose mmol/L*50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 52.6 mg/dL as posted
3.57 vs 3.14 Voglibose mmol/L @ 24wk*6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 64.3 mg/dL as posted
3.61 vs 2.92 Voglibose mmol/L*6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 65 mg/dL as posted
-4.08 vs -2.11 placebo mmol/L @ 24wk*i,c,d
NCT01646320 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -73.5 mg/dL as posted
2 other source trials
-2.06 vs -1.74 placebo mmol/L @ 24wk*5 mg
NCT01619059 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -37.1 mg/dL as posted
-1.51 vs -0.23 placebo mmol/L @ 24wk*5 mg
NCT00757588 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -27.2 mg/dL as posted
PPG 2h Change mg/dL
absolute change · mmol/L
No placebo or comparator arm
2.06 mmol/L @ 24wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TIDa,f,c
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 37.1 mg/dL as posted
show 3 more doses
2.19 mmol/L*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 39.4 mg/dL as posted
2.11 mmol/L @ 24wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 38 mg/dL as posted
2.2 mmol/L*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 39.6 mg/dL as posted
-1.68 mmol/L @ 24wk*f,c
NCT02104804 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -30.28 mg/dL as posted
PPG AUC Change Mgmin dL
absolute change · mg
No placebo or comparator arm
-70.4 mg @ 24wkAlogliptin 25 mg QD and Voglibose 0.2 mg TIDa,f,c
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
show 3 more doses
-82.2 mgAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-69 mg @ 24wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-77.5 mgAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-4702.2 mg @ 24wkf,c
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
Dropout rate
40.3%25 mg QDj
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 69 more results
36.6%12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
18.3%25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
21.1%12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
20%25 mg
NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3
11%
NCT00968708 · Phase 3
14.9%
NCT01456130 · Phase 3 · registry result, not featured evidence
44.3%25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
46.4%12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
9.8%Alogliptin Monotherapy
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
6.1%Metformin + Alogliptin Add-on Ther
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
6.6%Pioglitazone + Alogliptin Add-on T
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
36.3%25 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
38.8%12.5 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
20.5%25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence
37.2%12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence
17.5%alogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
17.1%alogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
0%25 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence
4.5%25 mg QD + 30 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence · combination
30%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
21.7%25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
24.2%12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
15.4%25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
13.1%25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
12.3%25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
11.5%12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
10.8%12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
13.8%12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
23.2%25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
17.1%25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
23.2%12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
19.6%25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
22.3%12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
21.4%25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
17.4%12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
25.3%25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
24.6%12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
—25 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—25 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—12.5 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—12.5 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
1.9%25 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
5.7%12.5 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
—Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
—Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
1.8%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
1.8%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
2.6%12.5 mg QD
NCT01263483 · Phase 2/3 · registry result, not featured evidence
6.3%25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
—25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
3.8%25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
4.8%12.5 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
3.8%50 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
6.3%6.25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
28.9%25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
27.3%12.5 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
31.1%100 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
38.6%50 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
38.6%6.25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
12.5%12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%Roflumilast + Alogliptin
NCT01664624 · Phase 1 · registry result, not featured evidence · combination
0%Roflumilast Alone
NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy
22.7%10 mgk
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 43 more results
25.1%5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
22.9%2.5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
29.6%10 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
35.8%5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
28.4%2.5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%
NCT02024477 · Phase 4 · registry result, not featured evidence
10.5%10mg
NCT02471404 · Phase 4 · registry result, not featured evidence
4.5%5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
5.7%
NCT02243176 · Phase 4 · registry result, not featured evidence
17.1%
NCT01608724 · Phase 4 · registry result, not featured evidence
2.4%
NCT01107886 · Phase 4 · registry result, not featured evidence
19.7%5 mg
NCT01006603 · Phase 4 · registry result, not featured evidence
19%
NCT01006590 · Phase 4 · registry result, not featured evidence · add on
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
5.7%Saxagliptin
NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy
7.5%dapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
8.6%
NCT02551874 · Phase 3 · registry result, not featured evidence · combination
12.6%
NCT02681094 · Phase 3 · registry result, not featured evidence · add on
8.2%
NCT02284893 · Phase 3 · registry result, not featured evidence · combination
25%
NCT01204775 · Phase 3 · registry result, not featured evidence
0%
NCT01434186 · Phase 3 · registry result, not featured evidence
—5 mg QD
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
6.8%Saxagliptin Plus Insulin
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
—DAPA + SAXA + MET
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
7.5%Dapa+Saxa+Met
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
7.2%5 mg
NCT01619059 · Phase 3 · registry result, not featured evidence · combination
—
NCT01606007 · Phase 3 · registry result, not featured evidence · combination
12.4%
NCT01128153 · Phase 3 · registry result, not featured evidence
5.8%
NCT00960076 · Phase 3 · registry result, not featured evidence · combination
61.4%
NCT00575588 · Phase 3 · registry result, not featured evidence · combination
5.6%5 mg
NCT00918879 · Phase 3 · registry result, not featured evidence
4.3%5 mg + Metformin XR 1500 mg
NCT00918138 · Phase 3 · registry result, not featured evidence · combination
11.8%5 mg
NCT00757588 · Phase 3 · registry result, not featured evidence · combination
50.6%
NCT00614939 · Phase 3 · registry result, not featured evidence
10.8%2.5 mg
NCT00885378 · Phase 3 · registry result, not featured evidence · combination
15%5 mg
NCT00374907 · Phase 3 · registry result, not featured evidence
7.7%5 mg
NCT00698932 · Phase 3 · registry result, not featured evidence
10.2%5 mg
NCT00661362 · Phase 3 · registry result, not featured evidence · combination
Discontinued due to AEs
4.7%25 mg QDj
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 69 more results
0.8%12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.5%25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
2.3%12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0%25 mg
NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3
5.6%
NCT00968708 · Phase 3
6%
NCT01456130 · Phase 3 · registry result, not featured evidence
8.4%25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
6.8%12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
1.1%Alogliptin Monotherapy
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
2%Metformin + Alogliptin Add-on Ther
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
0%Pioglitazone + Alogliptin Add-on T
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
6.2%25 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
7.4%12.5 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
3.6%25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence
6.2%12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence
9.6%alogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
4.5%alogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
—25 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence
—25 mg QD + 30 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence · combination
3.2%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
1.6%25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
0.8%12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
1.5%25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0%25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
3.1%25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0.8%12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.5%12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
3.8%12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.8%25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
3.7%25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
3.7%12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
3%25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
4.1%12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
2.9%25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
3.3%12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
2%25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
3%12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
—25 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—25 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—12.5 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—12.5 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
1%25 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
3.8%12.5 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
—Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
—Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
0.9%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
0.9%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
0%12.5 mg QD
NCT01263483 · Phase 2/3 · registry result, not featured evidence
3.8%25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
—25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
1.3%25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
1.2%12.5 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.5%50 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.5%6.25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.2%25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%12.5 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
4.4%100 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
6.8%50 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%6.25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
—25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
—25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
—25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
—12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
—12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%Roflumilast + Alogliptin
NCT01664624 · Phase 1 · registry result, not featured evidence · combination
0%Roflumilast Alone
NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy
2.8%10 mgk
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 43 more results
3.1%5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.6%2.5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.1%10 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.8%5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.9%2.5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
—
NCT02024477 · Phase 4 · registry result, not featured evidence
2.2%10mg
NCT02471404 · Phase 4 · registry result, not featured evidence
0.3%5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
0.8%
NCT02243176 · Phase 4 · registry result, not featured evidence
2%
NCT01608724 · Phase 4 · registry result, not featured evidence
—
NCT01107886 · Phase 4 · registry result, not featured evidence
4.2%5 mg
NCT01006603 · Phase 4 · registry result, not featured evidence
1.4%
NCT01006590 · Phase 4 · registry result, not featured evidence · add on
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—Saxagliptin
NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy
0.4%dapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
—
NCT02551874 · Phase 3 · registry result, not featured evidence · combination
3.4%
NCT02681094 · Phase 3 · registry result, not featured evidence · add on
0.4%
NCT02284893 · Phase 3 · registry result, not featured evidence · combination
—
NCT01204775 · Phase 3 · registry result, not featured evidence
—
NCT01434186 · Phase 3 · registry result, not featured evidence
—5 mg QD
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
1.7%Saxagliptin Plus Insulin
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
—DAPA + SAXA + MET
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
1.9%Dapa+Saxa+Met
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
0%5 mg
NCT01619059 · Phase 3 · registry result, not featured evidence · combination
—
NCT01606007 · Phase 3 · registry result, not featured evidence · combination
0.8%
NCT01128153 · Phase 3 · registry result, not featured evidence
0.7%
NCT00960076 · Phase 3 · registry result, not featured evidence · combination
2.6%
NCT00575588 · Phase 3 · registry result, not featured evidence · combination
—5 mg
NCT00918879 · Phase 3 · registry result, not featured evidence
—5 mg + Metformin XR 1500 mg
NCT00918138 · Phase 3 · registry result, not featured evidence · combination
2%5 mg
NCT00757588 · Phase 3 · registry result, not featured evidence · combination
5.9%
NCT00614939 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT00885378 · Phase 3 · registry result, not featured evidence · combination
—5 mg
NCT00374907 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT00698932 · Phase 3 · registry result, not featured evidence
1.8%5 mg
NCT00661362 · Phase 3 · registry result, not featured evidence · combination
Serious AEs
5.4%25 mg QDj
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 69 more results
6.1%12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.8%25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
3.8%12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
2.7%25 mg
NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3
33.6%
NCT00968708 · Phase 3
9%
NCT01456130 · Phase 3 · registry result, not featured evidence
11%25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
9.9%12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
2.2%Alogliptin Monotherapy
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
0%Metformin + Alogliptin Add-on Ther
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
1.6%Pioglitazone + Alogliptin Add-on T
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
16.3%25 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
16.7%12.5 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
0.9%25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence
3.6%12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence
1.8%alogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
1.9%alogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
8%25 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence
13.6%25 mg QD + 30 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence · combination
5%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
4.7%25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
3.9%12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
0.8%25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
4.6%25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
3.8%25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.5%12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
2.3%12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.5%12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0.6%25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
4.9%25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
0.6%12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
6.5%25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
2.5%12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
3.9%25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
2.8%12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
5.6%25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
5.4%12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
2%25 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
3.4%25 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
10.7%12.5 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
4.9%12.5 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
1%25 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
2.9%12.5 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
6.7%Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
5.6%Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
1.8%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
0.9%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
0%12.5 mg QD
NCT01263483 · Phase 2/3 · registry result, not featured evidence
1.3%25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
8.2%25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
7.9%12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
5.2%50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
2.1%6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
1.3%25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.4%12.5 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.5%50 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.5%6.25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.2%25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%12.5 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%100 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%50 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
2.4%6.25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
10%Roflumilast + Alogliptin
NCT01664624 · Phase 1 · registry result, not featured evidence · combination
0%Roflumilast Alone
NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy
12.2%10 mgk
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 43 more results
14.1%5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
12%2.5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.2%10 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
17%5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
10.8%2.5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.8%
NCT02024477 · Phase 4 · registry result, not featured evidence
12.5%10mg
NCT02471404 · Phase 4 · registry result, not featured evidence
7.1%5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
2.1%
NCT02243176 · Phase 4 · registry result, not featured evidence
1.8%
NCT01608724 · Phase 4 · registry result, not featured evidence
25.5%
NCT01107886 · Phase 4 · registry result, not featured evidence
11.4%5 mg
NCT01006603 · Phase 4 · registry result, not featured evidence
4.1%
NCT01006590 · Phase 4 · registry result, not featured evidence · add on
0%5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
3.8%5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence · combination
2.3%2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
1.6%2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
4.9%2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—Saxagliptin
NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy
12.8%dapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
6.2%
NCT02551874 · Phase 3 · registry result, not featured evidence · combination
2.4%
NCT02681094 · Phase 3 · registry result, not featured evidence · add on
3.9%
NCT02284893 · Phase 3 · registry result, not featured evidence · combination
0%
NCT01204775 · Phase 3 · registry result, not featured evidence
0%
NCT01434186 · Phase 3 · registry result, not featured evidence
5.1%5 mg QD
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
—Saxagliptin Plus Insulin
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
4.4%DAPA + SAXA + MET
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
—Dapa+Saxa+Met
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
4.6%5 mg
NCT01619059 · Phase 3 · registry result, not featured evidence · combination
1.1%
NCT01606007 · Phase 3 · registry result, not featured evidence · combination
2.3%
NCT01128153 · Phase 3 · registry result, not featured evidence
0%
NCT00960076 · Phase 3 · registry result, not featured evidence · combination
12.6%
NCT00575588 · Phase 3 · registry result, not featured evidence · combination
0%5 mg
NCT00918879 · Phase 3 · registry result, not featured evidence
2.2%5 mg + Metformin XR 1500 mg
NCT00918138 · Phase 3 · registry result, not featured evidence · combination
8.2%5 mg
NCT00757588 · Phase 3 · registry result, not featured evidence · combination
27.1%
NCT00614939 · Phase 3 · registry result, not featured evidence
1.4%2.5 mg
NCT00885378 · Phase 3 · registry result, not featured evidence · combination
5%5 mg
NCT00374907 · Phase 3 · registry result, not featured evidence
2.8%5 mg
NCT00698932 · Phase 3 · registry result, not featured evidence
2.8%5 mg
NCT00661362 · Phase 3 · registry result, not featured evidence · combination
Most frequent reported AEs
25 mg QDj
urinary tract infection 7% (placebo 7.8%)
diarrhoea 6.2% (placebo 5.4%)
nasopharyngitis 6.2% (placebo 4.7%)
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 69 more results
12.5 mg QD
arthralgia 6.9% (placebo 2.3%)
urinary tract infection 6.1% (placebo 7.8%)
headache 5.3% (placebo 4.7%)
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
25 mg QD
nasopharyngitis 7.6% (placebo 7.8%)
headache 6.8% (placebo 4.7%)
upper respiratory tract infection 4.5% (placebo 9.4%)
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
12.5 mg QD
nasopharyngitis 9% (placebo 7.8%)
headache 7.5% (placebo 4.7%)
back pain 5.3% (placebo 4.7%)
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
25 mg
headache 18.7% (placebo 10.5%)
hyperglycaemia 12% (placebo 11.8%)
diarrhoea 9.3% (placebo 9.2%)
NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3
renal impairment 7.5% (placebo 6.5%)
hypertension 7.1% (placebo 7.4%)
hypoglycaemia 6.2% (placebo 5.9%)
NCT00968708 · Phase 3
nasopharyngitis 35.8%
upper respiratory tract inflammation 11.9%
arthralgia 7.5%
NCT01456130 · Phase 3 · registry result, not featured evidence
25 mg
upper respiratory tract infection 10.3%
hypertension 7.6%
nasopharyngitis 7.6%
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
12.5 mg
upper respiratory tract infection 9.6%
nasopharyngitis 8.9%
diarrhoea 6.9%
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
hyperlipidaemia 6.5% (placebo 1.1%)
upper respiratory tract infection 5.4% (placebo 3.3%)
blood triglycerides increased 2.2% (placebo 1.1%)
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
upper respiratory tract infection 3% (placebo 3.3%)
blood triglycerides increased 2% (placebo 1.1%)
urinary tract infection 2% (placebo 6.5%)
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
hyperlipidaemia 21.3% (placebo 1.1%)
urinary tract infection 6.6% (placebo 6.5%)
upper respiratory tract infection 3.3% (placebo 3.3%)
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
25 mg
hypertension 14.5%
urinary tract infection 11.7%
nasopharyngitis 11.6%
NCT00306384 · Phase 3 · registry result, not featured evidence
12.5 mg
hypertension 14.8%
upper respiratory tract infection 11.6%
urinary tract infection 11.1%
NCT00306384 · Phase 3 · registry result, not featured evidence
25 mg QD
hyperglycaemia 17% (placebo 26.4%)
nasopharyngitis 6.3% (placebo 1.9%)
headache 5.4% (placebo 2.8%)
NCT01023581 · Phase 3 · registry result, not featured evidence
12.5 mg BID
hyperglycaemia 11.8% (placebo 26.4%)
headache 4.5% (placebo 2.8%)
creatinine renal clearance decreased 3.6% (placebo 3.8%)
NCT01023581 · Phase 3 · registry result, not featured evidence
alogliptin 12.5 mg BID + metformin 1000 mg BID
creatinine renal clearance decreased 7.9% (placebo 3.8%)
diarrhoea 7% (placebo 2.8%)
dyspepsia 7% (placebo 2.8%)
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
alogliptin 12.5 mg BID + metformin 500 mg BID
hyperglycaemia 7.5% (placebo 26.4%)
upper respiratory tract infection 7.5% (placebo 2.8%)
headache 6.6% (placebo 2.8%)
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
25 mg QD
nasopharyngitis 20% (placebo 4.2%)
anaemia 12% (placebo 4.2%)
constipation 8% (placebo 4.2%)
NCT00655863 · Phase 3 · registry result, not featured evidence
25 mg QD + 30 mg QD
hypoglycaemia 13.6% (placebo 0%)
nasopharyngitis 13.6% (placebo 4.2%)
constipation 9.1% (placebo 4.2%)
NCT00655863 · Phase 3 · registry result, not featured evidence · combination
Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
upper respiratory tract infection 7.2%
nasopharyngitis 6.9%
hypertension 5.9%
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
25 mg
headache 7% (placebo 4.7%)
upper respiratory tract infection 6.2% (placebo 3.9%)
abdominal pain upper 5.4% (placebo 1.6%)
NCT00328627 · Phase 3 · registry result, not featured evidence
12.5 mg
hypertriglyceridaemia 5.5% (placebo 2.3%)
hypertension 4.7% (placebo 3.1%)
urinary tract infection 4.7% (placebo 4.7%)
NCT00328627 · Phase 3 · registry result, not featured evidence
25 mg + 15 mg
influenza 6.2% (placebo 2.3%)
nasopharyngitis 6.2% (placebo 3.9%)
oedema peripheral 5.4% (placebo 1.6%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
25 mg + 30 mg
nasopharyngitis 6.9% (placebo 3.9%)
back pain 6.2% (placebo 3.9%)
influenza 6.2% (placebo 2.3%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
25 mg + 45 mg
diarrhoea 5.4% (placebo 8.5%)
headache 4.6% (placebo 4.7%)
oedema peripheral 4.6% (placebo 1.6%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
12.5 mg + 15 mg
hypertension 6.9% (placebo 3.1%)
nasopharyngitis 6.2% (placebo 3.9%)
dizziness 5.4% (placebo 3.1%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
12.5 mg + 30 mg
dizziness 3.8% (placebo 3.1%)
nasopharyngitis 3.8% (placebo 3.9%)
upper respiratory tract infection 3.8% (placebo 3.9%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
12.5 mg + 45 mg
back pain 9.2% (placebo 3.9%)
dizziness 4.6% (placebo 3.1%)
headache 4.6% (placebo 4.7%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
25 mg
headache 6.7%
urinary tract infection 3%
oedema peripheral 1.2%
NCT00395512 · Phase 3 · registry result, not featured evidence
25 mg + 30 mg
headache 12.2%
back pain 6.1%
urinary tract infection 5.5%
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
12.5 mg + 30 mg
headache 8.6%
urinary tract infection 3.7%
back pain 1.8%
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
25 mg QD
nasopharyngitis 7% (placebo 6.2%)
influenza 5.5% (placebo 4.1%)
oedema peripheral 5.5% (placebo 7.2%)
NCT00286494 · Phase 3 · registry result, not featured evidence
12.5 mg QD
oedema peripheral 6.1% (placebo 7.2%)
upper respiratory tract infection 5.6% (placebo 5.2%)
nausea 4.5% (placebo 2.1%)
NCT00286494 · Phase 3 · registry result, not featured evidence
25 mg QD
diarrhoea 3.4% (placebo 5.8%)
nasopharyngitis 3.4% (placebo 5.8%)
bronchitis 2.9% (placebo 1.9%)
NCT00286442 · Phase 3 · registry result, not featured evidence
12.5 mg QD
urinary tract infection 6.6% (placebo 3.8%)
nasopharyngitis 5.6% (placebo 5.8%)
upper respiratory tract infection 4.7% (placebo 6.7%)
NCT00286442 · Phase 3 · registry result, not featured evidence
25 mg QD
headache 5.6% (placebo 3%)
hypertension 5.6% (placebo 2%)
urinary tract infection 5.1% (placebo 3%)
NCT00286468 · Phase 3 · registry result, not featured evidence
12.5 mg QD
urinary tract infection 4.4% (placebo 3%)
diarrhoea 3.9% (placebo 0%)
hypertriglyceridaemia 3.9% (placebo 2%)
NCT00286468 · Phase 3 · registry result, not featured evidence
25 mg QD and 1-6 mg QD or BID
nasopharyngitis 37.5%
upper respiratory tract inflammation 10.5%
fall 7.9%
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
25 mg QD and 500 mg BID or 750 mg TID
nasopharyngitis 36.6%
diabetic retinopathy 6.9%
constipation 5.5%
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
12.5 mg QD and 1-6 mg QD or BID
nasopharyngitis 30.7%
upper respiratory tract inflammation 6.7%
back pain 5.3%
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
12.5 mg QD and 500 mg BID or 750 mg TID
nasopharyngitis 31%
back pain 6.3%
headache 6.3%
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
25 mg QD
nasopharyngitis 19.2%
upper respiratory tract inflammation 11.5%
back pain 3.8%
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
12.5 mg QD
nasopharyngitis 19%
gastroenteritis 3.8%
upper respiratory tract inflammation 1.9%
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
Alogliptin 25 mg QD and Voglibose 0.2 mg TID
nasopharyngitis 28.6%
back pain 5.7%
arthralgia 4.8%
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
nasopharyngitis 35.2%
upper respiratory tract inflammation 11.1%
back pain 7.4%
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
nasopharyngitis 11.5%
blood creatine phosphokinase increased 3.5%
dental caries 0%
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
nasopharyngitis 4.5%
blood creatine phosphokinase increased 0%
dental caries 0%
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
12.5 mg QD
nasopharyngitis 22.4%
eczema 1.3%
NCT01263483 · Phase 2/3 · registry result, not featured evidence
25 mg QD + 0.2 mg TID
nasopharyngitis 16.5%
eczema 0%
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
25 mg QD
nasopharyngitis 33%
headache 7.2%
upper respiratory tract inflammation 7.2%
NCT01263496 · Phase 2 · registry result, not featured evidence
12.5 mg QD
nasopharyngitis 28.7%
bronchitis 5.9%
back pain 5%
NCT01263496 · Phase 2 · registry result, not featured evidence
50 mg QD
nasopharyngitis 35.1%
blood creatine phosphokinase increased 8.2%
back pain 7.2%
NCT01263496 · Phase 2 · registry result, not featured evidence
6.25 mg QD
nasopharyngitis 30.2%
upper respiratory tract inflammation 8.3%
back pain 7.3%
NCT01263496 · Phase 2 · registry result, not featured evidence
25 mg QD
nasopharyngitis 12.5% (placebo 6.7%)
headache 6.3% (placebo 5.3%)
abdominal distension 3.8% (placebo 0%)
NCT01263470 · Phase 2 · registry result, not featured evidence
12.5 mg QD
nasopharyngitis 8.3% (placebo 6.7%)
flatulence 4.8% (placebo 2.7%)
urticaria 3.6% (placebo 0%)
NCT01263470 · Phase 2 · registry result, not featured evidence
50 mg QD
nasopharyngitis 10.1% (placebo 6.7%)
blood creatine phosphokinase increased 5.1% (placebo 2.7%)
abdominal distension 2.5% (placebo 0%)
NCT01263470 · Phase 2 · registry result, not featured evidence
6.25 mg QD
nasopharyngitis 6.3% (placebo 6.7%)
bronchitis 3.8% (placebo 1.3%)
flatulence 2.5% (placebo 2.7%)
NCT01263470 · Phase 2 · registry result, not featured evidence
25 mg QD
headache 8.9% (placebo 7.3%)
abdominal pain upper 6.7% (placebo 0%)
dizziness 6.7% (placebo 0%)
NCT00755846 · Phase 2 · registry result, not featured evidence
12.5 mg QD
rash 9.1% (placebo 2.4%)
abdominal pain 4.5% (placebo 0%)
arthralgia 4.5% (placebo 0%)
NCT00755846 · Phase 2 · registry result, not featured evidence
100 mg QD
nausea 11.4% (placebo 0%)
headache 9.1% (placebo 7.3%)
urinary tract infection 9.1% (placebo 9.8%)
NCT00755846 · Phase 2 · registry result, not featured evidence
50 mg QD
diarrhoea 7% (placebo 7.3%)
headache 7% (placebo 7.3%)
urinary tract infection 7% (placebo 9.8%)
NCT00755846 · Phase 2 · registry result, not featured evidence
6.25 mg QD
urinary tract infection 7.1% (placebo 9.8%)
abdominal pain upper 4.8% (placebo 0%)
dizziness 4.8% (placebo 0%)
NCT00755846 · Phase 2 · registry result, not featured evidence
25 mg
rash papular 25%
abdominal pain 0%
blood creatine phosphokinase increased 0%
NCT00957268 · Phase 1 · registry result, not featured evidence
25 mg
blood creatine phosphokinase increased 14.3%
haematocrit decreased 14.3%
haemoglobin decreased 14.3%
NCT00957268 · Phase 1 · registry result, not featured evidence
25 mg
headache 18.2%
fatigue 9.1%
nausea 9.1%
NCT00957268 · Phase 1 · registry result, not featured evidence
12.5 mg
diarrhoea 20%
neutrophil count decreased 20%
pyrexia 20%
NCT00957268 · Phase 1 · registry result, not featured evidence
12.5 mg
abdominal pain 25%
gastritis 12.5%
headache 12.5%
NCT00957268 · Phase 1 · registry result, not featured evidence
headache 30%
nausea 20%
constipation 10%
NCT01664624 · Phase 1 · registry result, not featured evidence · combination
nausea 50%
diarrhoea 40%
vomiting 30%
NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy
10 mgk
influenza 15.5% (placebo 15.1%)
nasopharyngitis 15.5% (placebo 14%)
headache 13.3% (placebo 12.3%)
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 37 more results
5 mg
influenza 16.2% (placebo 15.1%)
nasopharyngitis 14.7% (placebo 14%)
arthralgia 10.5% (placebo 6.7%)
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.5 mg
diarrhoea 15.1% (placebo 12.8%)
nasopharyngitis 14.6% (placebo 14%)
headache 14.1% (placebo 12.3%)
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
10 mg
arthralgia 16.3% (placebo 7.4%)
headache 16.3% (placebo 16.8%)
influenza 15.3% (placebo 6.3%)
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg
upper respiratory tract infection 15.1% (placebo 15.8%)
urinary tract infection 13.2% (placebo 8.4%)
headache 12.3% (placebo 16.8%)
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.5 mg
diarrhoea 13.7% (placebo 8.4%)
upper respiratory tract infection 11.8% (placebo 15.8%)
influenza 10.8% (placebo 6.3%)
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
10mg
nasopharyngitis 9.3%
NCT02471404 · Phase 4 · registry result, not featured evidence
5mg and 10mg
nasopharyngitis 9.9%
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
hyperlipidaemia 6.2%
hyperlipidaemia 3.7%
abdominal distension 1.2%
NCT02243176 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 2.7%
dizziness 2.6%
NCT01608724 · Phase 4 · registry result, not featured evidence
diabetes mellitus 6.5% (placebo 8.1%)
dizziness 4.5% (placebo 4.2%)
hypertension 4.2% (placebo 3.9%)
NCT01107886 · Phase 4 · registry result, not featured evidence
5 mg
nasopharyngitis 6.4%
arthralgia 4.7%
diarrhoea 4.2%
NCT01006603 · Phase 4 · registry result, not featured evidence
hypoglycaemia 6.8%
diarrhoea 6.1%
nasopharyngitis 5.4%
NCT01006590 · Phase 4 · registry result, not featured evidence · add on
5 mg
toothache 7.7% (placebo 0%)
acne 3.8% (placebo 0%)
animal bite 3.8% (placebo 0%)
NCT03199053 · Phase 3 · registry result, not featured evidence
5 mg
aphthous ulcer 3.8% (placebo 0%)
back pain 3.8% (placebo 2.6%)
colitis 3.8% (placebo 0%)
NCT03199053 · Phase 3 · registry result, not featured evidence
5 mg
nasopharyngitis 15.4% (placebo 2.6%)
asthma 7.7% (placebo 0%)
covid-19 7.7% (placebo 2.6%)
NCT03199053 · Phase 3 · registry result, not featured evidence · combination
2.5 mg
vitamin d deficiency 4.5% (placebo 6.6%)
nausea 3.4% (placebo 0%)
urinary tract infection 3.4% (placebo 5.3%)
NCT03199053 · Phase 3 · registry result, not featured evidence
2.5 mg
influenza 4.9% (placebo 2.6%)
bronchitis 1.6% (placebo 0%)
chronic sinusitis 1.6% (placebo 0%)
NCT03199053 · Phase 3 · registry result, not featured evidence
2.5 mg
covid-19 6.6% (placebo 2.6%)
upper respiratory tract infection 6.6% (placebo 2.6%)
urinary tract infection 4.9% (placebo 5.3%)
NCT03199053 · Phase 3 · registry result, not featured evidence
dapagliflozin 10 mg, saxagliptin 5 mg
urinary tract infection 13.7%
upper respiratory tract infection 10.1%
headache 7.9%
NCT02419612 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 7.7%
upper respiratory tract infection 5.2%
headache 3.7%
NCT02551874 · Phase 3 · registry result, not featured evidence · combination
glomerular filtration rate decreased 4.1%
pollakiuria 2.4%
urinary tract infection 2.4%
NCT02681094 · Phase 3 · registry result, not featured evidence · add on
nasopharyngitis 7.8%
headache 5.6%
urinary tract infection 4.3%
NCT02284893 · Phase 3 · registry result, not featured evidence · combination
oropharyngeal pain 50% (placebo 25%)
acne 25% (placebo 0%)
cough 25% (placebo 25%)
NCT01204775 · Phase 3 · registry result, not featured evidence
headache 50% (placebo 0%)
abdominal pain upper 25% (placebo 0%)
back pain 25% (placebo 0%)
NCT01434186 · Phase 3 · registry result, not featured evidence
5 mg QD
hypoglycaemia 21.8% (placebo 23.8%)
upper respiratory tract infection 2.6% (placebo 4.3%)
urinary tract infection 2.6% (placebo 0.9%)
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
urinary tract infection 9.4% (placebo 10%)
influenza 7.5% (placebo 7.5%)
headache 6.9% (placebo 8.1%)
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
5 mg
urinary tract infection 7.2% (placebo 6.8%)
headache 5.9% (placebo 7.4%)
nasopharyngitis 5.9% (placebo 4.9%)
NCT01619059 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 6.2% (placebo 9.4%)
diarrhoea 5.4% (placebo 3.9%)
hypertension 5.4% (placebo 1.6%)
NCT01128153 · Phase 3 · registry result, not featured evidence
diarrhoea 5.8%
urinary tract infection 5.1%
nasopharyngitis 4.3%
NCT00960076 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 10.7%
diarrhoea 5.8%
upper respiratory tract infection 5.8%
NCT00575588 · Phase 3 · registry result, not featured evidence · combination
5 mg
urinary tract infection 8.4% (placebo 9.4%)
NCT00918879 · Phase 3 · registry result, not featured evidence
5 mg + Metformin XR 1500 mg
cough 6.5%
NCT00918138 · Phase 3 · registry result, not featured evidence · combination
5 mg
urinary tract infection 7.6% (placebo 7.9%)
nasopharyngitis 6.3% (placebo 6.6%)
upper respiratory tract infection 6.3% (placebo 7.3%)
NCT00757588 · Phase 3 · registry result, not featured evidence · combination
hypoglycaemia 28.2% (placebo 29.4%)
anaemia 5.9% (placebo 8.2%)
hypertension 5.9% (placebo 5.9%)
NCT00614939 · Phase 3 · registry result, not featured evidence
5 mg
headache 25% (placebo 18.8%)
muscle spasms 25% (placebo 0%)
infusion site pain 20% (placebo 12.5%)
NCT00374907 · Phase 3 · registry result, not featured evidence
5 mg
upper respiratory tract infection 6.3% (placebo 7.7%)
NCT00698932 · Phase 3 · registry result, not featured evidence
5 mg
upper respiratory tract infection 6.7% (placebo 4.5%)
NCT00661362 · Phase 3 · registry result, not featured evidence · combination

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 4 versus Phase 2/3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eThe assessment timepoint is not available for both results.
  6. fTrial phases differ: Phase 3 versus Phase 2/3.
  7. gAssessment timepoints differ: 24 weeks versus 26 weeks.
  8. hAssessment timepoints differ: 12 weeks versus 104 weeks.
  9. iTrial phases differ: Phase 3 versus Phase 2.
  10. jPopulation comparability has not been reviewed for 65 of these studies.
  11. kPopulation comparability has not been reviewed for 38 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Alogliptin

Rescue 19.5% (n=128) vs 40.3% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 25 participants as posted
show 5 more results
9% (n=199) vs 12.4% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 18 participants as posted
15.7% (n=198) vs 28.3% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 31 participants as posted
20.6% (n=131) vs 40.3% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 27 participants as posted
9.7% (n=196) vs 12.4% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 19 participants as posted
14.9% (n=201) vs 28.3% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 30 participants as posted
HbA1c 6.5 or Less 2.3% (n=129) vs 0% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 3 participants as posted
show 7 more results
20.6% (n=131) vs 10.9% (n=64) placebo @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 27 participants as posted
20.6% (n=199) vs 5.2% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 41 participants as posted
14.1% (n=198) vs 7.1% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 28 participants as posted
2.3% (n=131) vs 0% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 3 participants as posted
17.3% (n=133) vs 10.9% (n=64) placebo @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 23 participants as posted
17.3% (n=197) vs 5.2% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 34 participants as posted
9.4% (n=203) vs 7.1% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 19 participants as posted
HbA1c 7 5 or Less 25.6% (n=129) vs 3.9% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 33 participants as posted
show 7 more results
67.2% (n=131) vs 39.1% (n=64) placebo @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 88 participants as posted
70.9% (n=199) vs 48.5% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 141 participants as posted
56.6% (n=198) vs 33.3% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 112 participants as posted
16.8% (n=131) vs 3.9% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 22 participants as posted
60.9% (n=133) vs 39.1% (n=64) placebo @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 81 participants as posted
64.5% (n=197) vs 48.5% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 127 participants as posted
46.3% (n=203) vs 33.3% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 94 participants as posted
HbA1c Decrease 0.5 54.3% (n=129) vs 31% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 70 participants as posted
show 9 more results
55% (n=131) vs 29.7% (n=64) placebo @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 72 participants as posted
64.3% (n=199) vs 26.8% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 128 participants as posted
58.9% (n=207) vs 26.9% (n=104) placebo @ 26wk*25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 122 participants as posted
50.5% (n=198) vs 26.3% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 100 participants as posted
53.4% (n=131) vs 31% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 70 participants as posted
50.4% (n=133) vs 29.7% (n=64) placebo @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 67 participants as posted
59.9% (n=197) vs 26.8% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 118 participants as posted
57.7% (n=213) vs 26.9% (n=104) placebo @ 26wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 123 participants as posted
47.3% (n=203) vs 26.3% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 96 participants as posted
HbA1c Decrease 1 0 36.4% (n=129) vs 13.2% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 47 participants as posted
show 9 more results
29.8% (n=131) vs 10.9% (n=64) placebo @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 39 participants as posted
36.7% (n=199) vs 12.4% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 73 participants as posted
30% (n=207) vs 8.7% (n=104) placebo @ 26wk*25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 62 participants as posted
29.8% (n=198) vs 13.1% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 59 participants as posted
31.3% (n=131) vs 13.2% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 41 participants as posted
28.6% (n=133) vs 10.9% (n=64) placebo @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 38 participants as posted
32.5% (n=197) vs 12.4% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 64 participants as posted
28.6% (n=213) vs 8.7% (n=104) placebo @ 26wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 61 participants as posted
18.7% (n=203) vs 13.1% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 38 participants as posted
HbA1c Decrease 1 5 17.8% (n=129) vs 4.7% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 23 participants as posted
show 9 more results
12.2% (n=131) vs 4.7% (n=64) placebo @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 16 participants as posted
18.6% (n=199) vs 5.2% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 37 participants as posted
11.6% (n=207) vs 5.8% (n=104) placebo @ 26wk*25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 24 participants as posted
12.1% (n=198) vs 7.1% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 24 participants as posted
16.8% (n=131) vs 4.7% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 22 participants as posted
8.3% (n=133) vs 4.7% (n=64) placebo @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 11 participants as posted
16.2% (n=197) vs 5.2% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 32 participants as posted
9.4% (n=213) vs 5.8% (n=104) placebo @ 26wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 20 participants as posted
6.4% (n=203) vs 7.1% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 13 participants as posted
HbA1c Decrease 2 0 8.5% (n=129) vs 0% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 11 participants as posted
show 9 more results
4.6% (n=131) vs 1.6% (n=64) placebo @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 6 participants as posted
7% (n=199) vs 3.1% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 14 participants as posted
2.4% (n=207) vs 3.8% (n=104) placebo @ 26wk*25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 5 participants as posted
6.1% (n=198) vs 4% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 12 participants as posted
8.4% (n=131) vs 0% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 11 participants as posted
2.3% (n=133) vs 1.6% (n=64) placebo @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 3 participants as posted
6.1% (n=197) vs 3.1% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 12 participants as posted
3.3% (n=213) vs 3.8% (n=104) placebo @ 26wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 7 participants as posted
2.5% (n=203) vs 4% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 5 participants as posted
MACE Composite 12.7% (n=2701) vs 13.4% (n=2679) placebo
responder rate · % of participants
NCT00968708 · Phase 3
HbA1c Less Than 6 5 28.4% (n=67) @ 52wk
responder rate · % of participants
No placebo or comparator arm
HbA1c of < 6.5%
NCT01456130 · Phase 3 · registry result, not featured evidence
Fasting Glucose Change mg/dL -0.58 mmol/L @ 52wk
absolute change · mmol/L
No placebo or comparator arm
NCT01456130 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -10.5 mg/dL as posted
HbA1c 7 0 or Less 27.1% (n=129) vs 6.2% (n=129) placebo @ 26wk25 mg
responder rate · % of participants
NCT00328627 · Phase 3 · registry result, not featured evidence
show 18 more results
24.4% (n=164) vs 33.7% (n=163) Pioglitazone 30 mg @ 26wk25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
22.7% (n=128) vs 6.2% (n=129) placebo @ 26wk12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
59.2% (n=878) vs 56.1% (n=869) Glipizide @ 26wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
55.5% (n=878) vs 47.4% (n=869) Glipizide @ 52wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
52.4% (n=878) vs 46.6% (n=869) Glipizide @ 78wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
48.5% (n=878) vs 42.8% (n=869) Glipizide @ 104wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
54.6% (n=130) vs 6.2% (n=129) placebo @ 26wk25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
53.1% (n=130) vs 6.2% (n=129) placebo @ 26wk25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
60% (n=130) vs 6.2% (n=129) placebo @ 26wk25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
62.8% (n=164) vs 33.7% (n=163) Pioglitazone 30 mg @ 26wk25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
56.4% (n=873) vs 56.1% (n=869) Glipizide @ 26wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
51.7% (n=873) vs 47.4% (n=869) Glipizide @ 52wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
48.8% (n=873) vs 46.6% (n=869) Glipizide @ 78wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
45.6% (n=873) vs 42.8% (n=869) Glipizide @ 104wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
49.2% (n=130) vs 6.2% (n=129) placebo @ 26wk12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
53.1% (n=130) vs 6.2% (n=129) placebo @ 26wk12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
61.5% (n=130) vs 6.2% (n=129) placebo @ 26wk12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
53.4% (n=163) vs 33.7% (n=163) Pioglitazone 30 mg @ 26wk12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
HbA1c Less Than 6 5 36.7% (n=90) vs 12.2% (n=90) placebo @ 16wk
responder rate · % of participants
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
show 2 more results
21.4% (n=98) vs 12.2% (n=90) placebo @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
30% (n=60) vs 12.2% (n=90) placebo @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination

+ 49 further endpoints in the CSV export.

Saxagliptin

HbA1c -0.58% (n=180) vs 0.13% (n=175) placebo @ 24wk10 mg
absolute change · percentage points
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 8 more results
-0.54% (n=98) vs 0.19% (n=95) placebo @ 24wk10 mg
Adjusted Mean Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.69% (n=186) vs 0.13% (n=175) placebo @ 24wk5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.46% (n=106) vs 0.19% (n=95) placebo @ 24wk5 mg
Adjusted Mean Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.84% (n=277) vs -0.34% (n=274) placebo @ 24wk5 mg
Adjusted Mean Change from Baseline
NCT00698932 · Phase 3 · registry result, not featured evidence
-0.59% (n=186) vs 0.13% (n=175) placebo @ 24wk2.5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.43% (n=102) vs 0.19% (n=95) placebo @ 24wk2.5 mg
Adjusted Mean Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.56% (n=74) vs -0.22% (n=84) placebo @ 12wk2.5 mg
Adjusted Mean Change From Baseline
NCT00885378 · Phase 3 · registry result, not featured evidence · combination
-0.86% (n=81) vs -0.44% (n=83) placebo @ 12wk
Adjusted Mean Change from Baseline
NCT00614939 · Phase 3 · registry result, not featured evidence
Fasting Plasma Glucose -1.14 vs 0.07 placebo mmol/L @ 24wk10 mg
absolute change · mmol/L
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -20.5 mg/dL as posted
show 6 more results
-1.22 vs 0.07 placebo mmol/L @ 24wk*5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -22.03 mg/dL as posted
-0.9 vs -0.17 placebo mmol/L @ 24wk5 mg
Adjusted mean change from Baseline
NCT00698932 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.17 placebo mmol/L @ 24wk*5 mg
Adjusted mean change from Baseline
NCT00698932 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -16.13 mg/dL as posted
-0.79 vs 0.07 placebo mmol/L @ 24wk*2.5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -14.31 mg/dL as posted
-0.52 vs -0.2 Metformin mmol/L @ 4wk*5 mg + Metformin XR 1500 mg
Adjusted mean change from baseline
NCT00918138 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -9.3 mg/dL as posted
-0.76 vs -0.23 placebo mmol/L @ 12wk*2.5 mg
Adjusted Mean Change from Baseline
NCT00885378 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -13.73 mg/dL as posted
Postprandial Glucose AUC -8137 vs -3291 placebo mg @ 24wk10 mg
absolute change · mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
-9586 vs -3291 placebo mg @ 24wk5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
-7534 vs -4255 placebo mg @ 24wk5 mg
Adjusted mean change from Baseline
NCT00698932 · Phase 3 · registry result, not featured evidence
-8891 vs -3291 placebo mg @ 24wk2.5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
Fasting Plasma Glucose -0.93 vs 0.34 placebo mmol/L @ 24wk10 mg
absolute change · mmol/L
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -16.75 mg/dL as posted
show 4 more results
-0.48 vs 0.34 placebo mmol/L @ 24wk*5 mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -8.67 mg/dL as posted
-1.14 vs -0.58 placebo mmol/L @ 24wk5 mg
Adjusted Change from Baseline
NCT00661362 · Phase 3 · registry result, not featured evidence · combination
-1.14 vs -0.58 placebo mmol/L @ 24wk*5 mg
Adjusted Change from Baseline
NCT00661362 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -20.52 mg/dL as posted
-0.81 vs 0.34 placebo mmol/L @ 24wk*2.5 mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -14.53 mg/dL as posted
Postprandial Glucose AUC -8084 vs -646.6 placebo mg @ 24wk10 mg
absolute change · mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 2 more results
-6896 vs -646.6 placebo mg @ 24wk5 mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
-6868 vs -646.6 placebo mg @ 24wk2.5 mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c 6.8% (n=21) vs 6.6% (n=21) placebo @ 6wk
absolute value · percentage points
Visit 2 - Week 6
NCT02024477 · Phase 4 · registry result, not featured evidence
HbA1c 6.7% (n=21) vs 6.5% (n=21) placebo @ 12wk
absolute value · percentage points
Visit 3 - Week 12
NCT02024477 · Phase 4 · registry result, not featured evidence
Time to Rescue Medication NA vs NA Glimepiride months @ 52wk10mg
time to event · months
NCT02471404 · Phase 4 · registry result, not featured evidence
show 2 more results
NA vs 21.3 Glimepiride months @ 156wkdapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
NA vs NA Glimepiride months @ 52wk5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
Rescue 18.6% (n=311) vs 21.4% (n=309) Glimepiride @ 52wk10mg
responder rate · % of participants
NCT02471404 · Phase 4 · registry result, not featured evidence
show 1 more result
8.3% (n=312) vs 21.4% (n=309) Glimepiride @ 52wk5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
HbA1c Less Than 7 Without GI AE 37% (n=230) vs 28.8% (n=229) Acarbose @ 24wk
responder rate · % of participants
NCT02243176 · Phase 4 · registry result, not featured evidence
PPG 2H -0.77 vs -1.07 Acarbose mmol/L @ 24wk
absolute change · mmol/L
NCT02243176 · Phase 4 · registry result, not featured evidence
show 2 more results
-0.65 vs 0.28 placebo mmol/L @ 24wk*
NCT01128153 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -11.66 mg/dL as posted
-0.65 vs 0.28 placebo mmol/L @ 24wk
NCT01128153 · Phase 3 · registry result, not featured evidence
HOMA-B 20.56 vs 13.08 Acarbose mU/mmol @ 24wk
absolute change · mU/mmol
NCT02243176 · Phase 4 · registry result, not featured evidence

+ 36 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alogliptin's landscape · Saxagliptin's landscape